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Africa is among the world’s fastest-growing 
economic regions with an estimated compound annual 
growth rate of 9.8% between 2010 and 2020 (Holt et al., 
2015, p.2).  In 2019, the five fastest growing economies 






Owusu, 2021, p.5).  Over the past twenty years, 
consumer spending, household income, urbanization, 
and other income measures have grown dramatically and 
are expected to continue (Holt et al., 2015, p.2).  As these 
metrics improve, experts predict related booms in the 
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Africa suffers from the highest disease burden in the world, with over half of the 
population lacking regular access to essential medicines (Owoeye, 2014, p.214; 
Chaudhuri & West, 2015, p.23).  Following two decades of reform, the continent 
has now emerged one of the fastest-growing economic regions, shifting public 
health focus toward non-communicable diseases (NCDs) (Holt et al., 2015, p.2).  
Among these NCDs is anemia, which has direct and indirect economic effects as 
large as 4.05% of GDP (Horton & Ross, 2003, p.51).  Encouraged by the rapid 
growth of liberalized markets, African governments and health officials are now 
considering local pharmaceutical production as a way to unlock the economic, 
social, and political benefits of improved public health.  This thesis explores two 
hypotheses: (a) tax incentives effectively induce greater foreign direct investment 
in East Africa, including pharmaceutical production, and (b) local pharmaceutical 
production in East Africa provides better access to essential medicines like 
haematinics (anti-anemia drugs) as measured by anemia prevalence in children 
under five.  To facilitate an empirical test of the latter, the former is assumed to be 
true based on the literature.  We study these questions using Ethiopia and Rwanda 
as representative countries.  Taking effect in 2012, Ethiopia’s Double Taxation 
Avoidance Agreement (DTAA) with India created local investment incentives via 
low rates for dividends, interest, royalties, and fees for technical services as 
compared to Rwanda, which has no such agreement.  We perform a difference-in-
differences (DID) regression using data from Demographic and Health Surveys 
(DHS) to estimate the causal relationship between favorable investment conditions 
and anemia rates among children.  Our results are inconclusive and suggest 
determinants of anemia are numerous and interconnected. 
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African drug market, with realistic assumptions as high 
as 200 percent growth for the next decade (Lucchini, 
2018).  By 2030, the African pharmaceutical industry is 
expected to be worth USD $56-70 billion (“African 
pharmaceutical,” 2020). 
Despite these optimistic numbers, however, “half of 
the population lack regular access to essential 
medicines” and 90% of all medicines are imported 
(Chaudhuri & West, 2015, p.23).  According to the 
World Health Organization (WHO), the proportional 
contribution of non-communicable diseases (NCDs) to 
the healthcare burden in Africa will rise by 21% through 
2030, driving demand of chronic prescription drugs 
(“African pharmaceutical,” 2018).  Among these NCDs 
is anemia, “a condition marked by a deficiency of red 
blood cells for hemoglobin in the blood” (“Anemia,” 
n.d.).  The WHO identifies roughly five anti-anemia 
medicines as essential (World Health Organization 
[WHO], 2019, p.33-34). 
This thesis studies the impact of locally-produced 
haematinics versus imports on public health outcomes 
via marketplace factors.  Using Ethiopia and Rwanda as 
representative countries, we explore the impact of 
government-imposed investment incentives on the local 
production market.  Taking effect in 2012, Ethiopia’s 
Double Taxation Avoidance Agreement (DTAA) with 
India created local investment incentives via low rates 
for dividends, interest, royalties, and fees for technical 
services as compared to Rwanda, which has no such 
agreement. 
Ethiopia and Rwanda are appropriate representative 
countries because they share common age structure, 
population growth rate, and gross domestic product 
(GDP) per capita among other factors (Central 
Intelligence Agency [CIA], 2021a; CIA, 2021d).  As we 
shall see, however, these two countries have sufficiently 
different political and economic legacies such that they 
provide a quasi-controlled experiment.  Ethiopia acts as 
the experiment group with its market-oriented 2011 
DTAA.  Having no DTAA with India, Rwanda, with its 
economic development strategy of African 
intracontinental investment, acts as the control.  Using a 
difference-in-differences (DID) regression model with 
data from Demographic and Health Surveys (DHS), we 
attempt to estimate the causal relationship between local 
pharmaceutical production and access to essential drugs 
like haematinics as measured by anemia prevalence in 
children under five. 
Our DID regression was supplemented by ordinary 
least-squares (OLS) regressions to confirm the 
determinants of anemia as presented in the literature.  
Both OLS and DID regressions were performed at 
several levels of outcome specificity and control against 
endogeneity.  Data extraction, recoding, and analysis 
were performed using STATA version 16 software.  
Results were reviewed for statistical significance at the 
95% confidence interval. 
Contrary to our hypothesis, the DID results show a 
strong positive correlation between the post-DTAA time 
period and the probability of moderate and severe 
anemia for Ethiopian children.  However, a number of 
concerns prevent an interpretation of this relationship as 
causal.  Though our data is inconclusive regarding the 
directionality and magnitude of the effect of local 
production, our empirical concerns suggest that the 
determinants of anemia are numerous and interrelated. 
2. Literature Review 
2.1. Anemia prevalence is negatively related to economic 
development 
Anemia is among the most common medical 
conditions globally, affecting more than two billion 
people in the developing world (Schady, 2012, p.887).  
Characterized by a shortage of oxygen-carrying red 
blood cells, anemic individuals often experience 
lethargy, decreased cognition, and lower physical 
capacity (“Anemia,” n.d.; Horton & Ross, 2003, p.63).  
A variety of empirical studies show a negative 
relationship between these biological effects and 
economic development though productivity, schooling, 
and mortality. 
A 1977 study by Gardner et al. in Sri Lanka found a 
significant negative correlation between iron deficiency 
anemia and physical working capacity as measured by 
heart rate and post-exercise lactate.  A 1979 study by 
Basta et al. in Indonesia found that wages were 
correlated with hemoglobin levels.  After iron treatment, 
those in the experiment group showed higher work 
output and decreased morbidity.  A similar study in 1994 
by Li et al. in China among female mill workers found a 
significant positive correlation between hemoglobin and 
productivity efficiency.  Iron-treated individuals had 
higher hemoglobin levels and lower working heart rates 
than the placebo group, indicating lower energy 
expenditure.  A 2003 study by Horton & Ross across ten 
developing countries found a causal relationship 
between iron deficiency anemia and (a) motor and 
mental impairment in children and (b) low productivity 
in adults.  The median total losses were estimated at 
4.05% of GDP based on lost or lowered wages.  A 2006 
study by Thomas et al. in Indonesia found that anemic 
individuals treated with iron supplements were better off 
physically, psycho-socially, and economically than those 
M. Bradley University of South Carolina Honors College (2021) 
3 
 
that received a placebo.  Males in the treatment group 
enjoyed wages 15% higher than the control.  A 2006 
study by Bobonis et al. in India found that iron 
supplementation improved preschool participation rates 
by 5.8%, suggesting a correlation between anemia and 
school attendance.  These results were supported by a 
2012 report by Alcázar in Peru that found economic 
losses due to anemia amounted to 0.62% of GDP, of 
which 46.3% was due to cognitive losses, 21.% due to  
loss and delay of schooling, 18.2% due to lower 
productivity in adults, and 13% due to delivery care of 
premature infants.  A 2018 study by Ejigu, Wencheko, 
and Berhane in Ethiopia found a positive correlation 
between anemia prevalence and poverty and low 
education - markers of poor economic development. 
2.2. Tax incentives effectively induce foreign direct 
investment 
Double taxation avoidance agreements have two 
objectives: (i) double taxation avoidance, which 
stimulates FDI and (ii) information sharing to prevent tax 
evasion, which stifles FDI (Shah & Qayyum, 2015, p.1; 
Dong, 2019, p.1).  Most such agreements, including the 
2011 Ethiopian-Indian DTAA, favor the country of 
residence in tax revenue by offering low rates in the 
country of source (Neumeyer, 2007, p.1501).  Low-
income countries rely on the expected FDI inflows to 
offset the otherwise expensive implementation of 
DTAAs.  Though relevant studies reach mixed 
conclusions, among these results are evidence that 
DTAAs are effective in promoting FDI. 
Generally speaking, Bora (2002), Blomstrom & 
Kokko (2003), Easson (2001), and Taylor (2000) find 
that fiscal incentives are significant determinants and 
motivators of FDI flows.  A 2003 study by Edmiston, 
Mudd, and Valev found that tax complexity has a 
negative effect on inward FDI.  Therefore, as suggested 
by Jones (1996) and Gravelle (1988), DTAAs should 
encourage FDI just by providing tax stability. 
A 2010 study by Botman et al. in East Asia found 
that reduced corporate income tax rates and low taxes on 
gross receipts (which include dividend and interest 
income) would attract inward FDI.  These conditions are 
similar to those offered by most DTAAs. Similarly, a 
2010 study by Barthel et al. across both developed and 
developing countries found that DTAAs increased FDI 
by between 27 and 31%.  A 2019 study by Dong across 
ten southeast Asian countries found a positive (though 
insignificant) correlation between FDI inflows and 
DTAAs. 
2.3. Local production provides better access to essential 
medicines than imports 
Given the proper conditions, such as economies of 
scale, a cohesive regulatory environment, and necessary 
infrastructure, among others, local pharmaceutical 
production is found to provide better access to essential 
medicines via lower costs and easier distribution 
(Mohamed, 2018, p.26; Conway et al., 2019, p.6). 
Kuanpoth (2007) and Chowdury & Kabir (2009) in 
Vietnam and Bangladesh, respectively, found that 
locally-produced medicines were considerably less 
expensive than their imported counterparts. A 2020 
study by Boateng et al. in Ghana found that a lack of 
locally-produced essential cancer drugs both limits 
availability and inflates price. 
Contingent on sufficient market access, a 2014 
simulation study by Chaudhuri & West in Ghana found 
that local producers could manufacture essential drugs at 
prices competitive with Indian exporters.  Likewise, a 
2019 study by McKinsey & Company researchers 
Conway et al. found that if scale and utilization are held 
constant, local production can lower prices as compared 
to imports.  Studies by Mujinja et al. (2014) and 
Chaudhuri et al. (2010) in Tanzania found that local 
production improves rural  and low-income access to 
medicines as compared to imports, especially those from 
India.  A 2017 study by Ewen et al. in Ethiopia found 
that local production was associated with 29% and 19% 
better availability in the public and private sectors, 
respectively, as compared to imports.  Patients paid 53% 
more than the government procurement price for 
imported medicines as compared to 17% more for those 
locally-produced.   
3. Background 
Global pharmaceutical production is highly 
concentrated, leaving most developing countries with 
either no industry at all or only relatively late-stage 
manufacturing (Chaudhuri & West, 2015, p.23).  African 
countries have historically been treated as a market for 
exports rather than production sites for foreign 
manufacturers (Chaudhuri & West, 2015, p.23).  In 
recent years, however, many African countries have 
attempted to spur local production to improve access by 
lowering costs. 
Simplistically speaking, pharmaceuticals may be 
either (a) branded or generic and (b) imported or locally-
produced.  These four combinations differ in investment 
model, manufacturing requirements, resulting price to 
payer, and ultimately consumer access (Chaudhuri & 
West, 2015, p.24; Conway et al., 2019, p.5). In Africa, a 
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growing market for generic drugs has supported 
government initiatives to attract foreign direct 
investment. 
Though largely driven by epidemiological needs, 
markets are sensitive to the policies of international 
health organizations, domestic governments, corporate 
producers, and local doctors.  Of particular importance is 
the “patent cliff,” or the date at which a branded 
pharmaceutical’s patent expires, thereby allowing 
generic manufacture to begin (Miglierini, 2019; “Patent 
cliff,” 2018).  Generics generally represent cheaper 
alternatives to branded drugs when both are produced 
domestically, but in many developing countries, branded 
manufacture takes place abroad and therefore requires 
importation.  The costs of imports, driven specifically by 
high logistics costs and taxes, mean that purchasing 
abroad may increase the price of drugs for final sale 
beyond the reach of all those who need it (Conway et al., 
2019).  However, the alternative – local production – 
also faces structural barriers including lack of 
infrastructure, access to qualified personnel, and power 
interruptions, among others which could impede access 
(Mohamed, 2018, p.16).   
The benefits of local production over imports are 
debated and largely country-specific.  Nowhere is this 
question of greater relevance than in sub-Saharan Africa, 
where as of 2019, as much as 70 to 90 percent of drugs 
were imported and over half of the population lacked 
access to essential medicines (Kaine & Nwokike, 2020; 
Chaudhuri & West, 2015, p.23).  Among these essential 
medicines are haematinics, drugs used to treat anemia. 
3.1. Anemia 
Anemia is a medical condition marked by a 
deficiency of red blood cells, which contain the oxygen-
carrying protein hemoglobin (“Anemia,” n.d.).  Of the 
estimated two billion cases of anemia in the developing 
world, half are attributed to iron deficiency (FAO/WHO, 
19992; WHO, 2009 as cited in Schady, 2012, p.887).  
Iron deficiency without anemia is believed to be equally 
widespread (Horton & Ross, 2003, p.52). 
Iron deficiency is the most common nutritional 
deficiency globally (Horton & Ross, 2003, p.52).  Iron is 
necessary for the production of red blood cells, and 
deficiency therefore often leads to anemia (Horton & 
Ross, 2003, p.52).  Prevalence rates are especially high 
among pregnant women and young children, especially 
given the continued prevalence of maternal 
undernutrition (Schady, 2012, p.887; Monterrosa et al., 
2018, p.1).  A 2018 study by Ejugi, Wencheko, and 
Berhane found that “anemia prevalence decreases as 
wealth index and educational level increase for both 
genders” (p.5). 
According to professor and World Bank advisor 
Norbert Schady, “traditionally, efforts to combat anemia 
in developing countries have focused on fortification or 
iron supplementation… [or the] provision of dietary 
supplements” (2012, p.887).  As a complement, this 
thesis explores the impact of marketplace factors on 
access to the haematinic drugs listed under section 10.1 
of the WHO’s 21st Model List of Essential Medicines 
(World Health Organization [WHO], 2019, p.33-34). 
The list includes four core medicines; ferrous salt, 
ferrous salt + folic acid, folic acid, and 
hydroxocobalamin; and a complementary list of 
erythopoeisis-stimulating agents (WHO, 2019, p.33-34). 
Anemia represents a particular concern among 
developing countries because of its impact on 
productivity. Common symptoms of iron deficiency 
anemia (IDA) include tiredness and lethargy due to the 
role of hemoglobin in transporting oxygen to the 
muscles, brain, and other tissues (Horton & Ross, 2003, 
p.63).  Anemic individuals therefore demonstrate limited 
physical and cognitive performance compared to their 
healthy counterparts (Horton & Ross, 2003, p.63). 
Anemia during pregnancy increases risk of preterm 
delivery, low birthweight, and infant mortality 
(Monterrosa et al., 2018, p.1).  Anemic mothers are also 
more likely to have anemic children, creating an 
intergenerational cycle of malnutrition (Monterrosa et 
al., 2018, p.1).  Observational studies of the relationship 
between IDA and mental capacity find that infants with 
moderate IDA score 0.5 to 1.5 standard deviations below 
those with sufficient iron on the Bayley scale of 
development (Horton & Ross, 2003, p.53).  Long-term 
studies in the United States and Indonesia also found 
impacts on motor development (Aukett et al., 1986; 
Idjradinata & Pollitt, 1993 as cited in Horton & Ross, 
2003, p.54).  These developmental delays are found to 
be at least partially reversible with iron therapy (Horton 
& Ross, 2003, p.58). 
If uncorrected, however, cognitive losses of iron 
deficiency are costly.  A study in Colombia found that a 
one standard deviation improvement in cognitive scores 
produced a 7-9% increase in hourly earnings 
(Psacharopoulos & Velez, 1992 as cited in Horton & 
Ross, 2003, p.51).  Similar studies in Kenya and 
Tanzania found improvements of 17-23% and 8-13%, 
respectively (Horton & Ross, 2003, p.51).  Because 
healthy children are more likely to remain in school, the 
benefits of improved cognitive development as a result 
of anemia treatment are compounded by indirect effects 
of greater education (Horton & Ross, 2003, p.61). 
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In terms of physical productivity, improvements of 
17% and 5% were observed among anemic rubber 
workers in Indonesia and cotton mill workers in China, 
respectively (Basta et al., 1979, p.916; Li et al., 1994, 
p.908).  A 2006 study by Thomas et al. in Indonesia 
found that anemic males given iron supplements earned 
15% higher wages than those who received a placebo 
(p.22).  A 2003 study by Aguayo, Scott, and Ross in 
Sierra Leone found that agricultural productivity losses 
caused by anemia in women generated losses of $19 
million annually (as cited in Caulfield et al., 2006). 
The combined loss from physical and cognitive 
underdevelopment due to IDA is estimated at 4.05% of 
GDP (Horton & Ross, 2003, p.51).  This estimate is even 
greater if one considers the economic and social costs of 
the 20% of maternal deaths in Africa attributable to IDA 
(Horton & Ross, 2003, p.71).  Though these valuations 
are reliant on a handful of well-controlled studies, 
scholars generally agree that anemia represents a large 
and growing public health concern (Horton & Ross, 
2003, p.72).   
Figure A1 from the Institute of Health Metrics and 
Evaluation (IHME) shows iron deficiency as the leading 
risk for years lived with disability in 2015 for children 
under five in Ethiopia, Rwanda, sub-Saharan Africa, and 
Brazil, Russia, India, and China, collectively referred to 
as BRIC, to which Africa is often compared (2019).  
Child underweight, wasting, and low birth weight also 
rank within the top eight, and are correlated with anemia 
(Yang et al., 2012, p.1; Monterrosa et al., 2018, p.1).  The 
United States is added as a comparison.  Figures A2 and 
A3 show that mild and moderate anemia are the leading 
impairments in Ethiopia, Rwanda, and sub-Saharan 
Africa in 2015 both for children under five and across 
age groups (IHME, 2019).  Impairments are those health 
concerns for which there are several underlying causes 
(IHME, 2018).  Anemia also ranks within the top ten for 
the BRIC countries, and the United States is again 
included for reference (IHME, 2019).  As of 2016, the 
World Bank estimates that as many as 50% of Ethiopian 
and 36.2% of Rwandan children under five are anemic 
(World Bank, 2016).  Our selection of anemia prevalence 
as our health measure of interest is justified by the 
similar health development status of our comparison 
countries Ethiopia and Rwanda and is motivated by the 
relevance of anemia to the developing world at large. 
3.2. African pharmaceutical market 
The African drug market is growing rapidly in 
response to political and economic changes over the past 
twenty years.  Between 2017 and 2030, prescription 
drugs generally are forecasted to grow at a compound 
annual growth rate (CAGR) of 6.5%, while generics 
specifically are expected to grow at 10% (“African 
pharmaceutical,” 2020).  With 15% of the global 
population and 24% of its disease burden, the region 
presents ample opportunity for “multinational 
corporations (MNCs) and local pharmaceutical 
companies seeking new sources of growth” (Ford, 2017, 
p.40; Holt et al., 2015, p.2). 
With a 1930 investment in Kenya, MNCs became 
the first to set up pharmaceutical manufacturing facilities 
in sub-Saharan Africa (Lartey et al., 2018, p.1).  In the 
1960s, indigenous companies appeared and set a period 
of exponential growth into motion (Lartey et al., 2018, 
p.1).  Since the 1970s, the African pharmaceutical sector 
has enjoyed substantial growth and now includes over 
300 facilities (Lartey et al., 2018, p.1). 
The development of the Indian market followed a 
similar timeline.  Manufacturing began in 1930, and in 
response to extensive planning and government funding, 
hit a period of exponential growth in the 1970s (Lartey 
et al., 2018, p.3).  The Indian pharmaceutical industry 
currently ranks third globally in terms of volume (Lartey 
et al., 2018, p.3). 
Unlike India, the African market is highly 
concentrated - 80% of manufacturers are located in just 
eight countries, which limits domestic self-sufficiency 
(Kaufman et al., 2021).  Even the most generous 
estimates only show 30% of sub-Saharan Africa’s 
medicine needs as met by local industry (Lartey et al., 
2018, p.1).  Instead, African drug demand is met by a 
combination of foreign aid donations and imports from 
Indian generics manufacturers and Chinese suppliers 
(Lartey et al., 2018, p.5; Ford, 2017, p.40).  This import 
reliance results in shortages during health emergencies 
and limits access to essential medicines, ultimately 
resulting in adverse public health outcomes (Lartey et al., 
2018, p.2; Chaudhuri & West, 2015, p.23).  In 2011, 
“61.2% of deaths in the WHO Africa Region…were 
caused by communicable diseases, maternal and 
neonatal diseases, and nutritional deficiencies that in 
many instances can be treated successfully with 
pharmaceutical agents” (Owoeye, 2014, p.214). 
Besides potentially improving access to essential 
medicines, local drug manufacturing contributes to 
poverty reduction by providing high-quality, 
technology-based jobs throughout the supply chain (Holt 
et al., 2015, p.2; Lartey et al., 2018, p.2).  Though the 
African Development Bank boasts that “Africa’s 
pharmaceutical industry is the fastest growing in the 
world,” the 2019 valuation of the sub-Saharan market at 
$14 billion is quite small in comparison to India ($19 
billion) and China ($120 billion) (Ford, 2017, p.41; 
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Conway et al., 2019, p.3).  Foreign firms often shy away 
from the comparatively challenging business 
environment of Africa, citing high transaction costs, 
institutional distance and uncertainty, and a “high 
liability of foreignness” (Gundelach & Hansen, 2020, 
p.175; Wrona & Trapczynski, 2012, p.298; Kostova, 
1999; Kostova & Zaheer, 1999 as cited in Gundelach & 
Hansen, 2020, p.175).  In response, many governments 
have developed initiatives to plan for and incentivize 
foreign investment. 
Since the 1990s, liberalization and regulatory 
reform has drawn the attention of European and Asian 
MNCs seeking first-mover advantages (Wrona & 
Trapczynski, 2012, p.298; Gundelach & Hansen, 2020, 
p.175).  The African pharmaceutical industry is 
projected to be worth over $40 billion by the next 
decade, due to a combination of four factors: (a) 
population growth (b) maturing of the business 
environment (c) rise of major cities and (d) improved 
healthcare capacity (Lartey et al., 2018, p.1; “African 
pharmaceutical,” 2020). 
3.2.1. Population growth 
Sub-Saharan Africa is expected to double its 
population by 2050 to 2.5 billion, representing more than 
one quarter of the world’s people (“Africa’s population,” 
2020).  Life expectancy is also rising (“Ford, 2017, p.40).  
These changes will produce more potential customers for 
pharmaceuticals.  Estimations of Africa’s population 
growth are considered reliable because of “population 
momentum,” meaning that the sheer number of women 
of childbearing age mitigates the effects of even 
conscious efforts to lower fertility rates (“Africa’s 
population,” 2020).  Africa’s population growth of 2.7% 
annually exceeds that of other developing regions 
including South Asia (1.2%) and Latin America (0.95%) 
(“Africa’s population,” 2020). 
3.2.2. Maturing of the business environment 
Following the socio-economic crises of the 1980s 
and early 1990s, African governments began 
comprehensive and systematic macroeconomic reform 
to liberalize markets (Anyanwu, 2006, p.43).  As the 
newly sanctioned capitalist markets grew more 
productive in allocating wealth, state investors began to 
target the region as both source and export markets 
(Anyanwu, 2006, p.43; Vickers, 2013, p.675).  Among 
these investors are firms headquartered in BRIC 
countries (Vickers, 2013, p.675).  “Mindful of the effect 
of drug imports on the balance of trade,” many 
governments offer tax exemptions and other benefits to 
incentivize local manufacturing (Holt et al., 2015, p.5; 
Sadana et al., 2018, p.21).  Increased market activity has 
contributed to improvements in GDP, consumer 
spending, and household income. 
3.2.3. Rise of major cities 
37% of African consumers are concentrated in just 
30 cities; experts predict these cities alone will have 
more consuming households by 2025 than Australia and 
the Netherlands combined (“African pharmaceutical,” 
2020).  This is critical to pharmaceutical demand 
because “cities enjoy better infrastructure and healthcare 
provision than rural areas, and urban middle-class 
households have more purchasing power and are quicker 
to adopt modern medicines” (Holt et al., 2015, p.5; 
Mohamed, 2018, p.15). 
3.2.4. Improved healthcare capacity 
Between 2005 and 2012, African healthcare 
capacity grew by 70,000 hospital beds, 16,000 doctors, 
and 60,000 nurses (Lucchini, 2018).  The shifting burden 
of disease to NCDs drives the demand for chronic 
prescription drugs, which are becoming more easily 
available through pharmacy chains backed by private-
equity investors (“African pharmaceutical,” 2018; Holt 
et al., 2015, p.5).  New public and private insurance 
programs help increase access and affordability of these 
new medications (Sadana et al., 2018, p.21). 
Africa’s pharmaceutical market and economic 
development are linked: as individuals become 
wealthier, they seek better and more frequent access to 
healthcare.  However, besides the wealthy, even poor 
individuals need access to medication.  Despite rapid 
improvements to capitalist markets and growing 
consumer power, Africa remains the world’s poorest 
region and home to more than half of the world’s 
extreme poor (Vickers, 2013, p.67; “The number,” 
2018).  The question of whether local production or 
imports meets these pressing needs better is a focus of 
this study. 
3.3. Generic drug market 
A generic drug is a medication produced to have the 
same dosage, safety, strength, route of administration, 
quality, and performance characteristics as an existing 
brand-name drug (“Generic drug facts,” 2018).  Generics 
are produced after the expiration of the branded drug’s 
patent (National Association of Pharmaceutical 
Manufacturers [NAPM], 2009, p.138).  Because the 
producers bear the cost of neither research and 
development nor extensive marketing, generic drugs are 
typically less expensive.  For these reasons among 
others, generic drugs are gaining market share at the 
expense of branded medications in many African 
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countries (Holt et al., 2015, p.6).  Generic anti-anemia 
medicines are comprised of generally simple, small 
molecules.  Production of drugs of this nature is fairly 
straightforward because the economic and “technical 
challenges would vary for more complex products, such 
as combination drugs, injectables, and vaccines” 
(Conway et al., 2019, p.1). 
The rise in popularity of generics is due to four key 
shifts: (a) recommendation by medical professionals (b) 
expansion of insurance programs (c) government 
support and (d) compulsory licensing.   
3.3.1. Recommendation by medical professionals 
Medical professionals increasingly prescribe 
generic drugs and recognize them as useful alternatives 
(Holt et al., 2015, p.6).  This is partially due to the rising 
incidence of chronic lifestyle diseases, which generates 
greater demand for prescriptions (Lucchini, 2018).  
South Africa, for example, requires pharmacists to 
inform private patients about generic alternatives (Holt 
et al., 2015, p.6).  It is important to note, however, that 
in some cases negative perceptions of local products 
(which are usually generics) result in customers paying 
“more for international branded generics as a proxy for 
quality” (Mohamed, 2018, p.16; Kaufman et al., 2021). 
3.3.2. Expansion of insurance programs 
As national insurance programs expand due to 
economic and political development, more individuals 
are covered.  Public-private partnerships are also 
expanding as healthcare markets liberalize (Sadana et al., 
2018, p.21).  As low-cost alternatives to branded drugs, 
generics are popular among insurers (Holt et al., 2015, 
p.6). 
3.3.3. Government support 
Governments support generics and domestic 
manufacturing capacity because of the economic, 
political, and health benefits of industry growth (Holt et 
al., 2015, p.6).  According to the National Association of 
Pharmaceutical Manufacturers, “because generics lower 
total funder expenses, the use of generics makes funds 
available to be used for new innovative drugs from 
originator companies,” thereby providing governments 
the budgetary flexibility necessary to support drug 
access for more citizens (2009, p.144).  Government 
subsidy is especially important in developing countries, 
as pharmaceuticals are often the largest household health 
expenditure and a major cause of household 
impoverishment (WHO, n.d.)  Since 2013, the African 
generic market has grown by 9% annually (Lartey et al., 
2018, p.1). 
3.3.4. Compulsory licensing 
In 1994, the Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) Agreement required signatories 
to recognize patents for all eligible pharmaceutical 
products (Owoeye, 2014, p.214).  However, in response 
to public health needs, the Doha Declaration was signed 
in 2001 to grant “member states of the World Trade 
Organization the right to adopt legislation permitting the 
use of patented material without authorization by the 
patent holder, a provision known as ‘compulsory 
licensing’” (Owoeye, 2014, p.214).  Because most 
African countries are on the World Trade Organization’s 
list of low-income countries, this exempts them from 
complying with patents for pharmaceuticals until 2033 
(United States Agency for International Development 
[USAID], 2016, p.1).  African countries are therefore 
incentivized to develop local manufacturing capacity 
now to enjoy the benefits of compulsory licensing while 
international intellectual property law is flexible 
(Owoeye, 2014, p.214).  Rwanda is an exception in that 
it has fully aligned its intellectual property law with that 
of TRIPS and other international conventions to which it 
is a signatory (Owoeye, 2014, p.215).  This may improve 
communication with international suppliers (see: 6.2.2.3 
Intellectual property law).  
Despite these growth factors, at present, local 
manufacturing capacity in Africa remains 
underdeveloped.  Most countries are still reliant on 
imports to meet public health needs, as foreign 
manufacturers prefer an arms-length approach to market 
entry given (real or perceived) barriers to entry (Owoeye, 
2014, p.214; Chaudhuri & West, 2014, p.23).  Even the 
incentives of compulsory licensing have been 
insufficient to spur significant capacity building 
(Owoeye, 2014, p.215).  In fact, pharmaceutical MNCs 
have raised few concerns over TRIPS compliance 
because the dearth of infrastructure in Africa makes large 
scale compulsory licensing unlikely (Owoeye, 2014, 
p.215).  As such, recent studies show that only about 
40% of public sector and 60% of private sector 
pharmaceutical outlets offer generics (Owoeye, 2014, 
p.214).  In the private sector, generics are on offer at 6.7 
times the international reference prices – low as 
compared to originator brand medicines, which can be as 
much as 20.5 times the reference prices (Owoeye, 2014, 
p.214). 
Although African countries can import generics, 
current issues with TRIPS compliance in India may soon 
reduce the availability of these drugs for export 
(Owoeye, 2014, p.214-215).  According to professor 
Olasupo Owoeye, “as emerging economies in Asia begin 
to implement a more protectionist intellectual property 
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framework, Africa is ill-advised to continue relying on 
generic manufacturers in Asia for access to affordable 
pharmaceuticals” (2014, p.217).  Combined with the 
increasing tendency for MNCs to produce their own 
generics and price erosion across the industry, the need 
for African manufacturing capacity is urgent (NAPM, 
2009, p.143-144; Owoeye, 2014, p.217).  Local 
production also reduces foreign dependence, which 
improves public health by making supplies more reliable 
(Chaudhuri & West, 2014, p.24; USAID, 2016, p.1). 
Though local production offers many advantages, 
MNCs are quick to point out its many challenges.  Africa 
suffers from cost disadvantages including lack of skilled 
labor, high cost of inputs, lack of infrastructure, and high 
cost of financing (Chaudhuri & West, 2014, p.24).  As 
Chaudhuri and West explain, “it is a widely held view in 
health policy circles that if African countries with higher 
costs try to promote local production then prices will be 
higher than that of imported medicines and hence, local 
production will negatively impact access” (2014, p.24).  
Conversely, advocates of local production argue that a 
lower profit margin can be offset by a larger volume of 
sales (Chaudhuri & West, 2014, p.24).  In rural areas, 
locally-produced medicines are used more often than 
their imported equivalents, suggesting a direct 
correlation between local capacity and access (Lartey et 
al., 2018, p.2). 
3.3.4.1. Implications for investment 
Not only may compulsory licensing improve access 
to essential medicines, but such local production may 
even be profitable.  Traditionally, “foreign 
manufacturers located in countries such as India have 
treated [African] countries essentially as a market for 
their exports rather than taking the initiative to produce 
there” (Chaudhuri & West, 2015, p.23).  An estimated 
70 to 90% of sub-Saharan Africa’s pharmaceutical needs 
are currently met through imports – far exceeding the 
foreign dependence of other developing regions such as 
India and China who import just 5 and 20%, respectively 
(Conway et al., 2019, p.1).  Local African producers hold 
just 20% of the pharmaceutical market primarily due to 
capacity constraints, but also because aid organizations 
tend to purchase from Western firms or India (Ford, 
2017, p.40).  Foreign MNCs enjoy better reputations and 
thus “dominate the market despite charging higher 
prices” (Chaudhuri & West, 2015, p.34).  Though many 
foreign exporters, unlike African manufacturers, are 
GMP-compliant, locally-produced drugs are generally 
safe and effective (“LABOPHAR eyes,” 2010). 
Though currently drugs are cheaper when imported, 
some studies suggest that “with comparable facilities 
some drugs tomorrow could be cost competitive or even 
cheaper than imports from India,” especially in the case 
of generics or basic oral solids such as haematinics 
(Conway et al., 2019, p.5).  A 2019 study by McKinsey 
& Company in Ethiopia, for example, found that an 
imported drug’s landed price includes the Indian 
manufacturer’s price “plus a more than 20% markup as 
a result of freight, duties, and value-added tax” (p.5).  If 
that same drug were produced in Ethiopia, “the raw 
materials would still be imported, but the import costs 
would be lower because of their relatively low value” 
(Conway et al., 2019, p.5).  Adding in additional costs of 
lower manufacturing efficiency and producer margins, 
the total cost at the end of manufacturing is higher than 
in India (Conway et al., 2019, p.5).  However, domestic 
production reduces logistics costs for distributors, so at 
the point of entry into the local supply chain, the 
Ethiopian-manufactured drug is 5 to 15% more 
affordable for the end user (Conway et al., 2019, p.5).  
This scenario is illustrated by Figure A4.  It is important 
to note, however, that this situation is largely theoretical 
due to low current capacity and utilization rates in Africa 
(Conway et al., 2019, p.6). 
3.4. Hypotheses 
Based on our background research, our hypotheses 
are (a) tax incentives effectively induce greater foreign 
direct investment in East Africa, including 
pharmaceutical production, and (b) local pharmaceutical 
production provides better access to essential drugs like 
haematinics as measured by anemia prevalence in 
children under five.  To facilitate the empirical testing of 




(a) Tax incentives effectively induce greater 
foreign direct investment in East Africa, 
including pharmaceutical production 
(b) Local pharmaceutical production in 
East Africa provides better access to 
essential drugs like haematinics as 
measured by anemia prevalence in children 
under five. 
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3.5. Ethiopia, Rwanda, and India 
Ethiopia is the fastest growing economy in sub-
Saharan Africa and the second largest population (World 
Bank, 2021).  Likewise, Rwanda is also rapidly growing 
due to political and economic reforms over the past two 
decades (CIA, 2021d).  Both countries act as major 
trading partners for India, enjoying both FDI and imports 
in the pharmaceutical sector. 
3.5.1. Country comparison empirical justification 
DID regressions require the parallel trends 
assumption, wherein changes in the treatment group over 
time are expected to be the same as the control group if 
no treatment were administered.  Similarities between 
Ethiopia and Rwanda support this assumption as much 
as possible given the limitations of the experimental 
design (see: 4. Empirical Methodology).   
In the mid-1990s, Ethiopia and Rwanda appeared 
poorly positioned for economic development (Reynolds, 
2018).  Having just emerged from violent civil wars, 
both countries ranked among the world’s poorest with 
GDP per capita of less than $150 (Reynolds, 2018).  Yet 
as economist Oliver Reynolds explains, “fast forward 
just 25 years and…they are arguably the two most 
economically dynamic countries in the whole of Africa” 
(2018).  With annual growth rates of 10% and 7% in 
Ethiopia and Rwanda respectively over the past decade, 
their success is touted as proof of Africa’s ability to 
punch above its weight (Reynolds, 2018). 
In both countries, economic development started at 
the top with the long-term policies of technocratic 
leaders (Reynolds, 2018).  The idea was to move up the 
value chain – kickstarting a positive feedback loop of 
capital accumulation (Reynolds, 2018). Industrialization 
from an agrarian economy to manufacturing and services 
would create jobs for the rapidly-growing and urbanizing 
middle class. With higher incomes, those individuals 
would then engage in the local and international 
economy as consumers. 
Despite differences in size – Ethiopia’s 110 million 
citizens are more than eight times Rwanda’s 12.9 million 
– the countries’ population structures are remarkably 
similar (CIA, 2021a, CIA, 2021d).  With over 39% of 
each population under 14 years of age and a median age 
of just 19, Ethiopia and Rwanda are rich in young talent.  
Plus, this pool is only growing – both countries have 
population growth rates of roughly 2%, with about one-
fifth concentrated in urban areas (CIA, 2021a; CIA, 
2021d).  Urbanization rates are also high at 4.63% in 
Ethiopia and 2.86% in Rwanda (CIA, 2021a; CIA, 
2021d).   Combined with rising life expectancies and 
falling infant morality rates, the Ethiopian and Rwandan 
workforce is expanding, creating new opportunities for 
labor intensive industries like manufacturing (World 
Bank, 2016). 
Economically, the countries have enjoyed similar 
improvements to wealth at the household level since the 
mid-1990s, with real GDP per capita now estimated at 
just over $2,220 (CIA, 2021a; CIA, 2021d).  It is 
important to note, however, that Ethiopia’s large 
population results in significantly larger total GDP.  In 
both countries, industry (which includes pharmaceutical 
manufacturing) now accounts for roughly one-fifth of 
GDP (CIA, 2021a; CIA, 2021d).  A full comparison is 
available in Table 1. 
3.5.2. Ethiopia 
Ethiopia’s development has focused primarily on 
manufacturing, which it hopes will represent 20% of 
GDP by 2025 (Reynolds, 2018).  The government’s 
industrializing strategy is designed to provide 
international access to the domestic market, and thus 
includes agreements with key state investors and trade 
partners, such as India.  This approach attempts to 
capitalize on the opportunities presented by Ethiopia’s 
changing demographic and health conditions, while 
building local capacity to address related challenges. 
3.5.2.1. Development status 
Although Ethiopia has enjoyed an average annual 
growth rate of 14% over the last ten years, making it one 
of the fastest-growing economies globally, the country 
remains quite poor (ITA, 2020a).  Over 70% of 
Ethiopians are employed in the agricultural sector, more 
than 80% live in rural areas, and as of 2014, nearly 30% 
of lived below the poverty line (CIA, 2021a).  Ethiopia 
also suffers from a high burden of disease, especially 
major infectious diseases like malaria, though this is 
gradually shifting to NCDs (CIA, 2021a). 
Over the past twenty years, Ethiopia has slowly 
begun privatizing state-owned enterprises, making a 
significant liberalizing shift from a planned economy 
towards “market-based reforms and new flexibility” 
(ITA, 2020a).  Government efforts to attract FDI from 
China, Turkey, India, and the EU have resulted in 
improvements to infrastructure, enabling growth in the 
industry and service sectors (CIA, 2021a).  In fact, 
industry and manufacturing’s share of GDP, driven 
primarily by construction, rose consistently from 2005 to 
reach 28.1% in the 2018/2019 Ethiopian fiscal year 
(ITA, 2020a). As of 2017, the industrial production 
growth rate was an optimistic 10.5%, suggesting 
continued improvement (CIA, 2021a).  This industrial 
development is particularly important given Ethiopia’s 
growing and increasingly wealthy middle class (ITA,  
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Table 1. Ethiopia and Rwanda comparison. 
Development markers and their values 
Geography Ethiopia Rwanda 
Location 
East Africa; borders Djibouti, 
Kenya, Somalia, South Sudan, 
Sudan 
Central East Africa; borders 
Uganda, Tanzania, Burundi, and 
the DRC 
Size Just less than twice Texas Smaller than Maryland 
Landlocked Yes Yes 
Economic development 
Population 110 million 12.9 million 
      Growth rate 2.5% 1.8% 
      Urban concentration 17.4% 21.7% 
      Urbanization rate 4.63% 2.86% 
      Living in rural areas 80% 82.7%1 
      Employed in agriculture 70% 75.3% 
      Below poverty line 30% 39% 
Real GDP PPP $248.9 billion $28.1 billion 
      Real GDP per capita $2,221 $2,227 
      Industry percentage of GDP 21.6% 17.6% 
Import status $15.59 billion; 6.4% from India $1.922 billion; 7% from India 
Annual growth rate, last decade 14% 7% 
Primary development strategy 
Privatization and market-based 
reform; focus on manufacturing2, 3 
Transition into regional trade, 
logistics, conference hub; focus 
on manufacturing and services2, 4 
Ease of Doing Business Ranking 159th 38th 
DTAA with India Yes5 No 
Health development 
Age structure 
70% of population under 30; 
median age 19 
60% of population under 24; 
median age 19 
Anemia prevalence, children under 5  50%6 36%6 
Burden of disease 
Significant; shifting to NCDs but 
continued significance of 
infectious diseases 
Significant; shifting to NCDs but 
continued significance of 
infectious diseases 
Health expenditure percentage of GDP 3.3% 7.5% 
Trust in institutions 
Institutions global ranking (1 best) 126th7 36th7 
Public services score (1 best), considers 
access to medicine 
8.88 7.48 
Prevalence of bribery among healthcare 
and medical services 
35%9 1%9 
Notes: Information reflects the most recent data available from the CIA World Factbook (CIA, 2021a; CIA, 2021d) unless otherwise noted. 
1World Bank, 2019b. 2Reynolds, 2018. 3ITA, 2020a. 4ITA, 2020b. 5DTAA, 2011.  6World Bank, 2016.  7World Bank, 2019a.  8World Bank, 
2017.  9World Bank, 2013. 
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2020a; Mubila & Aissa, 2011 as cited in Addae & 
Addae, 2013, p.29). 
Despite these changes, however, the 2020 World 
Bank’s Ease of Doing Business report ranked Ethiopia 
an unenviable 159th out of 190 countries (ITA, 2020a). 
According to the World Economic Forum, “burdensome 
customs administrative procedures, the high cost of 
logistics, and access to credit and foreign exchange” 
remain major challenges for small- and medium-
enterprises (ITA, 2020a).   
3.5.2.2. Pharmaceutical industry 
Ethiopian industrial policy views local production 
of essential medicines as a strategic priority (Bate, 2008 
as cited in Gebre-Mariam, Tahir, & Gebre-Amanuel, 
2016, p.78).  Local production began in 1964 with the 
founding of EPHARM, a joint venture between the 
Ethiopian government and British company Smith & 
Nephew (see: Case Study B1) (Gebre-Mariam, Tahir, & 
Gebre-Amanuel, 2016, p.66).  Following the 
establishment of the democratic government, local 
manufacturing experienced rapid growth between 1995 
and 2004 (Gebre-Mariam, Tahir, & Gebre-Amanuel, 
2016, p.67).  The new government, however, had not yet 
implemented policies or regulatory mechanisms “to 
control dumping of cheaper and substandard products,” 
so “the prices of local products were not competitive” 
(Gebre-Mariam, Tahir, & Gebre-Amanuel, 2016, p.67).  
Four of the ten new companies subsequently “foreclosed 
for failure to service their loan obligations” (Gebre-
Mariam, Tahir, & Gebre-Amanuel, 2016, p.67). 
In 2005, GOE implemented a variety of policy 
reforms to correct for institutional failures (Gebre-
Mariam, Tahir, & Gebre-Amanuel, 2016, p.68).  
Improvements to the business environment resulted in 
new joint ventures, including Cadila Pharmaceuticals 
(see: Case Study B3) (Gebre-Mariam, Tahir, & Gebre-
Amanuel, 2016, p.68).   
As of 2016, the Ethiopian pharmaceutical industry 
consisted of 15 manufacturers, all of which have 
relatively low production capacity, relying on “labor-
intensive, step-by-step manual manufacturing, with 
semi-automated production lines” (Gebre-Mariam, 
Tahir, & Gebre-Amanuel, 2016, p.69).  The Ethiopian 
industry is limited to secondary manufacturing 
combining imported APIs and excipients into final 
dosage forms (Gebre-Mariam, Tahir, & Gebre-Amanuel, 
2016, p.65-70). Appendix B provides a detailed review 
of foreign investment strategies. 
“Although the Ethiopian pharmaceutical market 
grew on average 20% per annum from 2007 to 2011,” it 
is valued at just $600M primarily because of low per 
capita income (Gebre-Mariam, Tahir, & Gebre-
Amanuel, 2016, p.72; Conway et al., 2019, p.7).  The 
country is heavily reliant on imports across the economy: 
over the past ten years, imports have increased 12.5% 
annually, resulting in a 316% increase in value from 
2010 to 2018/2019 and creating significant current 
account deficits (International Trade Administration 
[ITA], 2020; CIA, 2021a).   
Advocates estimate that an increase in local share of 
production from 15 to 40% would improve trade 
balances by $150 to $200 million annually (Conway et 
al., 2019, p.1).  According to the International Trade 
Association, such improvements are quite possible, as 
“factors of production in Ethiopia such as land, labor, 
and energy costs are low relative to African and other 
global markets” (2020).  Furthermore, industrialization 
plans include expanding power generation capacity and 
increased FDI due to tax incentives (CIA, 2021a).  
Critics, however, dismiss local production over quality 
concerns (Gebre-Mariam, Tahir, & Gebre-Amanuel, 
2016, p.78).  Table 2 summarizes Ethiopia and Rwanda’s 
pharmaceutical capacities using criteria established in a 
2018 report by Nazeem Mohamed, Chairman of the 
Federation of East African Pharmaceutical 
Manufacturers Association.  Appendix C expands on 
Table 2. 
3.5.2.3. DTAA 
In 2011, Ethiopia signed a double taxation 
avoidance agreement (DTAA) with India.  By 
streamlining tax procedures and introducing low, stable 
rates, the agreement was celebrated as fostering 
economic cooperation and FDI, especially in high-value 
sectors like technology and services (“India and 
Ethiopia,” 2011; DTAA, 2011).  Though signed in 2011, 
the agreement came into effect October 2012 in Ethiopia 
and April 2013 in India (DTAA, 2011). 
The agreement sets maximum income tax rates at 
7.5% for dividends and 10% for interest, royalties, and 
fees for technical services in the country of source 
(ASEAN Briefing, 2011).    An enterprise’s “country of 
source” is the one in which it earns profits through a 
permanent establishment situated therein (DTAA, 2011).   
Examples of permanent establishments include 
branches, factories, and subsidiaries (“India and 
Ethiopia,” 2011).   
Dividends, interest, royalties, and fees for technical 
services may be taxed in both the country of residence 
and the country of source, but when the beneficial owner 
of such income is a resident of the country of residence, 
the tax caps in the country of source are 7.5% (dividends) 
and 10% (interest, royalties, and fees for technical 
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services) (DTAA, 2011).   This streamlines tax reporting  
and prevents excess tax costs for MNCs.  It also 
necessitates the sharing of information including 
banking data, domestic legislation changes, and 
investment proposals (DTAA, 2011; ASEAN Briefing, 
2011).  Double taxation is avoided by allowing 
individuals to, on the tax documents of their country of 
residence, deduct an amount equal to the tax paid in the 
income’s country of source (DTAA, 2011). 
The provisions for fees for technical services are of 
particular importance for Ethiopia, given the 
government’s focus on development via manufacturing.  
Table 2. Ethiopia and Rwanda pharmaceutical production capacity. 
Pharmaceutical capacity factors and their description 
Current status Ethiopia Rwanda 
Local manufacturing 
Yes; secondary manufacturing of final 
dosage forms1 
No; zero production since 20132 
Import Reliance 
Local production holds roughly 15% 
market share, for which 95% of APIs 
and raw packaging materials are 
imported3, 1 
Fully-import reliant; most imports 
made via state-owned procurement 
agencies4 
Capacity factors 
Economies of scale 
Open tender procurement system does 
not favor local production; other local 
production incentives (i.e. tax breaks, 
customs exemptions) are positive signs 
of government support5, 6 
Streamlining of business registration to 
one day encourages FDI; incentives 
available for investment in special 
economic zones16, 17 
      Potential market 
Membership in COMESA offers 
preferential tariffs among 19 member 
countries; potential trading partners 
with the Middle East due to proximity7 
Membership in East African 
Community (EAC) used as a 
constraint; demonstrated preference for 
EAC in import duties, hiring, visas18 
Regulatory environment 
Fragmented and highly complex 
resulting in MNC preference for local 
partners, but large regulatory budget 
and efforts at reform8, 3 
Complex and inefficient; inconsistent 
application of incentives18, 19 
Input materials 
Almost all inputs imported including 
machinery and technical assistance; 
foreign reliance results in higher 
logistics, insurance, inventory, and 
interest costs7, 1, 9 
Government payments often delayed; 
reliant on imports for APIs, excipients, 
and machinery (pre-2013)18, 19 
Capital investment, financing 
Acute foreign exchange shortage 
delays procurement and results in 
exposure to price fluctuations; high 
inflation; difficult loan approval; 
reliance on foreign aid10, 1, 11, 12, 13 
High interest rates; limited capital 
markets18 
Skilled personnel 
Low wages attractive to investors, but 
largely offset by low productivity due 
to limited technical skills14, 9 
Shortage of skilled labor18 
Infrastructure 
Limited transportation infrastructure 
creates long lead times and higher 
communication, inventory, and 
insurance costs; low capacity 
utilization increases cost per unit15, 1 
Limited transportation infrastructure; 
exceptionally high electricity costs18, 19 
Access to technology 
Introduction of new logistics 
management systems improved 
inventory management; general lack of 
reliable data10, 8 
General lack of reliable data8 
Notes: 1Gebre-Mariam, Tahir, & Gebre-Amanuel, 2016, p.65-83.  2Hazikimana, 2021.  3Conway et al., 2019, p.1, 7.  4Uwizeyimana et al., 
2021, p.3.  5ITA, 2020a.  6“Local pharma,” n.d.  7EFDRE, 2015, p.3-4.  8Lartey et al., 2018, p.5-6.  9Chaudhuri & West, 2015, p.31-32.  10ITA, 
2020a.  11Pletcher, 2020.  12Hailu, 2017, p.37.  13Owoeye, 2014, p.215.  14Gebre, 2018.  15Holt et al., 2015, p.9.  16USDOC, 2018.  
17Steenbergen & Javorcik, 2017, p.2.  18ITA, 2020b.  19USAID, 2016, p.1-3.   
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The DTAA describes fees for technical services as 
payments for “managerial or technical or consultancy 
services, including the provision of services of technical 
and other personnel” (DTAA, 2011).  These types of 
services are often required for the establishment of new 
manufacturing facilities in developing countries.  
Royalties are similarly important, including “the right to 
use industrial, commercial, or scientific equipment, or 
for information concerning industrial, commercial, or 
scientific experience” as is common in joint ventures and 
licensing arrangements (DTAA, 2011). 
Given the development status of the two countries, 
it is much more likely that India invests in Ethiopia than 
the reverse.  But the 2011 DTAA still benefits both 
parties: Indian MNCs save on tax costs and enjoy better 
access to information when investing in Ethiopia.  The 
FDI then boosts the Ethiopian economy through the 
strengthening of domestic industry. 
3.5.3. Rwanda 
Rwanda’s development strategy is broader than that 
of Ethiopia and includes support for both the 
manufacturing and services sectors (Reynolds, 2018).  
Though its Vision 2050 initiative and National Strategy 
for Transformation set the ambitious goal of becoming a 
high-income nation, Rwanda has done comparatively 
little to encourage FDI (Reynolds, 2018).  As a member 
of the East African Community, Rwanda has, to the 
detriment of larger international investors, favored the 
investment of its neighbors (Reynolds, 2018).  As such, 
it does not currently have a DTAA with India. 
3.5.3.1. Development status 
Though Rwanda boasts strong GDP growth of over 
7% annually over the past two decades, the country 
remains far from its goal of  high- or even middle-income 
status (ITA, 2020b).  Rwanda is predominantly rural, and 
over 75% of the population is employed in agriculture 
(CIA, 2021d).  Some 39% of Rwandans live below the 
poverty line, and as of 2019, per capita income was just 
$818 (CIA, 2021d; ITA, 2020b). Like Ethiopia, Rwanda 
enjoys favorable projections of human capital, with over 
60% of the population under age 24 and improving 
mortality metrics (CIA, 2021d; World Bank, 2016).  
Though shifting towards NCDs, Rwanda continues to 
struggle with major infectious diseases (CIA, 2021d). 
The government’s focus on manufacturing and 
services growth has yielded results – in 2019, the 
economy grew more than 9% (ITA, 2020b).    Over the 
past decade, “the percentage of foreign assistance in the 
country’s annual budget has dropped from over 80%...to 
39.5% in the 2020/2021 national budget” (ITA, 2020b). 
This self-sufficiency is thanks to the growth of the 
services sector, which by 2017 accounted for more than 
51% of GDP (CIA, 2021d).  As of 2020, Rwanda ranked 
relatively high on the World Bank’s Ease of Doing 
Business Index at 38th – the second-best in sub-Saharan 
Africa (ITA, 2020b).   
Economic outlooks for Rwanda are generally 
positive, citing low inflation, a reputation for low 
corruption, and a relatively low external debt-to-GDP 
ratio (ITA, 2020b).  However, because of a reliance on 
imports, “the Rwandan government faces chronic and 
large current account deficits” (ITA, 2020b).  In 2019, 
imports exceeded $2.7 billion, an increase of over 10% 
from the previous year due to infrastructure projects and 
industry development that require capital and 
intermediary goods (ITA, 2020b).  The government 
views the deficit as a short-term evil necessary for the 
development of domestic capacity. 
3.5.3.2. Pharmaceutical industry 
According to a 2016 report by USAID, Rwanda’s 
pharmaceutical manufacturing capability is “fledgling” 
with “limited capacity” for only “non-complex 
products” (p.1).  Like other developing countries, 
Rwanda remains reliant on imports from India and China 
(Uwizeyimana et al., 2021, p.3).  In 2019, Rwanda spent 
over $97 million on drug imports, and estimates for 2024 
are as high as $102.5 million (Uwizeyimana et al., 2021, 
p.3).  Facing foreign exchange shortages, the Rwandan 
government supports local pharmaceutical 
manufacturing as a way to reduce import expenses 
(Uwizeyimana et al., 2021, p.3).   
Although liberalizing change in the last two decades 
has made conducting business easier for both locals and 
foreigners, the pharmaceutical sector has not yet caught 
on (Uwizeyimana et al., 2021, p.3).  Rwanda still 
struggles with “a huge investment gap in the 
pharmaceutical sector,” relying instead on state-owned 
procurement agencies who typically purchase abroad 
(Uwizeyimana et al., 2021, p.3).  As of 2018, there was 
no local production by MNCs (see: Case Studies B2 and 
B4) (US Department of Commerce [USDOC], 2018). 
3.5.4. India 
Over the past thirty years, India’s pharmaceutical 
industry has grown from nearly nonexistent to now the 
world’s third-largest industry by volume (“India’s 
generics,” 2012, p.41).  Exports account for roughly $9 
billion of the industry’s $20 billion valuation (“India’s 
generics,” 2012, p.41).  Of total Indian exports to Africa, 
drugs represent 11.1% (“India’s generics,” 2012, p.41). 
Unlike other developing countries, India’s 
pharmaceutical industry is heterogeneous and includes 
several large, export-oriented MNCs (Chaudhuri & 
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West, 2015, p.27).  India is the world’s primary provider 
of generic medicines and manufacturers straights for all 
minerals, including haematinics like folic acid (“India’s 
generics,” 2012, p.41; Monterrosa et al., 2018, p.7). 
Indian investment in Africa began in 1977 with the 
expansion of Ranbaxy Laboratories into Nigeria 
(“India’s generics,” 2012, p.41).  Since then, cooperation 
has grown, with Africa now accounting for 16% of all 
Indian pharmaceutical exports (“India’s generics,” 2012, 
p.41).  Cipla, India’s second-largest pharmaceutical 
company, is the continent’s largest supplier of anti-
malarial drugs (“India’s generics,” 2012, p.41).  
According to news source African Business, “at an 
India-African conference held in Assis Ababa in May 
[2011], Prime Minister Manmohan Singh announced 
that India will create a $700 million line of credit to help 
in training and building new institutions across Africa” 
(“India’s generics,” 2012, p.41).  Despite trade 
agreements and capacity building, though, Indian 
medicines sold in African import markets are generally 
more expensive than those available in the domestic 
Indian market, suggesting local production is favorable 
for access (Chaudhuri & West, 2015, p.33). 
4. Empirical Methodology 
Recall our hypotheses (a) tax incentives effectively 
induce greater foreign direct investment in East Africa, 
including pharmaceutical production, and (b) local 
pharmaceutical production in East Africa provides better 
access to essential drugs like haematinics as measured by 
anemia prevalence in children under five.  To facilitate 
our empirical test of the latter, the former is assumed to 
be true based on the literature.  Data analysis was 
conducted using Demographic and Health Surveys for 
Ethiopia and Rwanda.  First, we performed ordinary 
least-squares (OLS) regressions to explore the 
determinants of hemoglobin levels and anemia.  We then 
ran a difference-in-differences (DID) regression to 
estimate the causal effect of the 2011 Ethiopian DTAA 
on anemia levels of children under five.   
4.1. Data sources 
This study used four datasets from the Demographic 
and Health Surveys.  For both the treatment and control 
groups, Ethiopia and Rwanda, data was needed from 
before and after the intervention.  The intervention being  
the 2012 implementation of the 2011 Ethiopian-Indian 
DTAA, the datasets selected were the following: 
 2011 Ethiopian Demographic and Health 
Survey, Children’s Recode  
 2016 Ethiopian Demographic and Health 
Survey, Children’s Recode  
 2010 Rwandan Demographic and Health 
Survey, Children’s Recode  
 2015 Rwandan Demographic and Health 
Survey, Children’s Recode 
Though ideally the before/after datasets would be 
collected in the same year, the DHS program performs 
surveys in cycles which vary by country.  DHS surveys 
use a “multistage stratified cluster sampling technique” 
explained in detail in each respective report (Worku, 
Tesema, & Teshale, 2020, p.2). 
4.2. Data management and analysis 
We conducted background research using electronic 
databases, including Google Scholar, EBSCO Host, and 
Academic Search Complete, among others.  After 
identifying an initial set of applicable studies, we then 
used a “snowballing” technique to locate additional 
sources – tracing backward references cited in the initial 
articles and forward tracing works that cited the original 
(van Essen, van Oosterhout, & Heugens, 2013, p.536).  
We also used data visualization tools available through 
the World Health Organization, World Bank, and 
Institute for Health Metrics and Evaluation. 
Data extraction, recoding, and analysis were 
performed using STATA version 16 software.  Using the 
95% confidence level, p-values of ≤ 0.05 and |t-stats| of 
≥ 2 were considered thresholds of statistical significance.  
Because the study was conducted using publicly 
available survey data, ethical approval and participant 
consent were not required.  We did, however, request and 
receive permission from the DHS Program to download 
and use the data for secondary analysis. 
4.3. Ordinary least-squares (OLS) regressions 
We first performed OLS regressions to explore the 
determinants of hemoglobin and anemia levels.  This 
provided a baseline understanding of country, region, 
and year fixed effects.  This preliminary analysis 
supports the robustness of our later DID regressions. 
4.3.1. Study variables 
Our selection of variables is based on research 
performed by health experts in the United States and 
Ethiopia.  Though not exhaustive, our variable selection 
accounts for many of the major determinants of anemia. 
4.3.1.1. Outcome variables 
OLS regressions were performed using three types 
of outcome variables for children under five: (i) 
hemoglobin level, (ii) split moderate and severe anemia, 
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and (iii) combined moderate and severe anemia.  
Hemoglobin level was provided by the DHS reports as a 
continuous measure adjusted for altitude in g/dl with one 
implied decimal (USAID, 2013, p.21).  From a child’s 
reported hemoglobin level, the DHS reports then created 
a new discrete variable “anemia level”, which 
categorizes children as having mild, moderate, or severe 
anemia based on the following thresholds: 
 Severe:  Below 7.0 g/dl 
 Moderate: Between 7.1 g/dl and 9.9 g/dl 
 Mild: Between 10.0 g/dl and 10.9 g/dl (USAID, 
2013, p.79) 
From this DHS variable we created three binary 
variables: (i) child severe anemia (ii) child moderate 
anemia (iii) child severe or moderate anemia, where 1 
indicates a child whose hemoglobin falls into the 
relevant threshold and 0 indicates one who does not.  
Outcome variables are described in Table 3. 
4.3.1.2. Independent variables 
Our study included seven individual and two 
community-level factors as independent variables as 
described in Table 4.  OLS regressions are used to 
confirm these variables’ correlation with anemia for later 
inclusion as protections against endogeneity in the DID 
Table 3. Description and measurement of the outcome variables. 
Outcome variables and their description/categorization 
Child hemoglobin level Hemoglobin level adjusted by altitude in g/dl with one implied decimal1 
Child moderate anemia 
Recoded from the DHS discrete variable “anemia level”; “1” if hemoglobin levels 
between 7.1 g/dl and 9.9 g/dl, “0” if not. 
Child severe anemia 
Recoded from the DHS discrete variable “anemia level”; “1” if hemoglobin levels 
below 7.0 g/dl, “0” if not. 
Child severe or moderate 
anemia 
Recoded from the DHS discrete variable “anemia level”; “1” if hemoglobin levels 
below 9.9 g/dl, “0” if not. 
Notes: 1USAID, 2013, p.21 
  
Table 4. Description and measurement of the independent variables. 
Independent variables and their description/categorization 
Individual level variables 
Child birth order A child’s order of birth among those in its family. 
Family size Total number of children in a child’s family. 
Mother hemoglobin 
level 
Hemoglobin level of the child’s mother adjusted by altitude in g/dl with one implied 
decimal. 
Child age Child’s age in months. 
Child weight-for-height 
percentile 
Calculated using the CDC Standard Deviation-derived Growth Reference Curves 
derived from the NCHS/FELS/CDC Reference Population with two implied decimal 
places1. 
No education 
Recoded from the DHS discrete variable “highest educational level attended”; “0” if 
some education, “1” if no education. 
Poor 
Recoded from the DHS discrete variable “wealth index,” a composite measure of a 
household’s cumulative living standard as measured by asset ownership1.  “0” if 
“richest,” “richer,” or “middle,” “1” if “poorest” or “poorer”. 
Community-level variables 
Residence 
Recoded from the DHS discrete variable “de facto type of place of residence”; “0” if 
“urban”, “1” if “rural”. 
Region De facto region of residence. 
Notes: 1USAID, 2013, p.78, 18. 
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regressions.  Independent variables are described in 
Table 4. 
4.4. Difference-in-difference (DID) regressions 
Sometimes referred to as the “controlled before-
and-after study,” the difference-in-differences (DID) 
model “is a quasi-experimental design that makes use of 
longitudinal data from treatment and control groups to 
obtain an appropriate counterfactual to estimate a causal 
effect” (Mailman School, n.d.).  It is often used to 
estimate the effect of an intervention by comparing 
changes in outcome over time between an intervention 
and control group, especially “when randomization on 
the individual level is not possible” (Mailman School, 
n.d.).  By accounting for differences between the 
treatment and control group the beginning of the study 
period, the DID method “removes biases in post- 
intervention period comparisons…that could be the 
result from permanent differences between those 
groups” (Mailman School, n.d.).  This technique is 
shown graphically in Figure A5. 
Our study uses the Ethiopian and Rwandan DHS 
datasets as repeated cross-sectional data.  Recalling that 
our treatment is the 2011 Ethiopian-Indian DTAA, a 
child’s country determines its treatment status; “Treat,” 
T=0,1, where 0 indicates Rwandan children (control 
group), and 1 indicates Ethiopian children (treatment 
group).  Children are observed in two time periods; 
“After,” t=0,1 where 0 indicates pre-treatment (2010 in 
Rwanda and 2011 in Ethiopia) and 1 indicates post-
treatment (2015 in Rwanda and 2016 in Ethiopia).  The 
basic DID equation is 
(1)   Y= β0 + β1(t) + β2(T) + β3(t × T) + ε 
where Y is the outcome variable, β0 is a baseline average 
of the control group, β1 is the time trend of the control 
group, β2 is the difference between the treatment and 
control pre-intervention, and ε is an error term containing 
all determinants of Y omitted from the model (Mailman 
School, n.d., Albouy, n.d., p.1).  The coefficient of 
interest is β3, which estimates the effect of the treatment 
on the outcome.  β3 is the DID estimator calculated as 
“the difference in average outcome in the treatment 
group before and after treatment minus the difference in 
average outcome in the control group before and after 
treatment” (Albouy, n.d., p.3). 
4.4.1. Required assumptions 
The DID method requires three assumptions.  
Firstly, the error term must, on average, be zero; E(ε) = 
0.  Secondly, the error term must be uncorrelated with all 
other variables in the equation; Cov (x, ε) = 0.  Most 
importantly, the DID method relies on the parallel trends 
assumption, which states that “in the absence of 
treatment, the unobserved differences between treatment 
and control groups are the same over time” (Mailman 
School, n.d.).  Should any of these assumptions not hold, 
then the β3 estimator cannot confidently be said to be 
unbiased.  Because these assumptions refer to 
unobservable qualities, they may be difficult or 
impossible to verify (see: 6. Discussion) (Albouy, n.d., 
p.4). 
5. Results 
Having found statistically significant correlations 
between mother hemoglobin level, child age, child 
weight-for-height percentile, parent education, wealth 
status, and residence, our OLS regressions support the 
existing literature on the determinants of anemia.  Our 
DID regressions, however, provided inconclusive results 
regarding the efficacy of the DTAA in reducing anemia. 
5.1. OLS regressions 
A 2018 study conducted by Ejigu, Wencheko, and 
Berhane using the 2011 Ethiopian DHS dataset found 
“education level, age, wealth index, [and] BMI…to be 
significant predictors of anemia prevalence” (p.1).  A 
similar study conducted by Worku, Tesema, and Teshale 
in 2020 using the 2016 Ethiopian DHS dataset found that 
living in a rural area is also significantly associated with 
anemia prevalence (p.2).  Because anemic mothers are 
more likely to have anemic children, we also include the 
mother’s hemoglobin level (Monterrosa et al., 2018, 
p.1).  To these variables we added child birth order, 
family size, and child age to account for potential 
endogeneity related to family wealth, access to proper 
nutrition, or biological development.  The OLS 
regressions are for the equation  
(2)    Y = I0 + I 1X1 + I 2X2 + I 3X3 + I 4X4 + I 5X5 + I 6X6 +  
         I 7X7 + I 8X8 + ε 
where I0 is a constant, I1 is the coefficient for child birth 
order, I2 is the coefficient for family size, I3 is the 
coefficient for mother hemoglobin level, I4 is the 
coefficient for child age, I5 is the coefficient for child 
weight-for-height percentile (substituted for BMI), I6 is 
the coefficient for no education, I7 is the coefficient for 
poor, I8 is the coefficient for residence, and ε is an error 
term containing all determinants of Y omitted from the 
model.  Table 5 shows the coefficients when Y is the 
combined binary variable for moderate or severe anemia, 
though results were similar for regressions using child 
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hemoglobin level, child moderate anemia, and child 
severe anemia. 
Regressions were performed four times, each time 
adding a level of control against unobservable 
characteristics.  Column (1) shows the coefficients of our 
various independent variables with no attention to fixed 
effects, making these values subject to endogeneity 
concerns.  In Column (2), we add the binary variable 
“Country,” which assigns “0” if a child is Ethiopian and  
“1” if a child is Rwandan.  The OLS regression equation 
is thus adjusted to 
(3)    Y = I0 + I1X1 + I2X2 + I3X3 + I4X4 + I5X5 + I6X6 +  
         I7X7 + I8X8 + I9X9 + ε 
where I9 is the coefficient for country.  In Column (3), 
we add the discrete variable “Region,” which accounts 
for the non-temporal, unobservable characteristics 
unique to each of Ethiopia’s nine geographical regions 
and two administrative cities using the Tigray region as 
the comparison (CSA & ICF, 2016, p.2).  At this point, 
residence becomes statistically significant, aligning with 
the research performed by Worku, Tesema, and Teshale.  
The regression equation is thus adjusted to 
(4)    Y = I0 + I1X1 + I2X2 + I3X3 + I4X4 + I5X5 + I6X6 +  
         I7X7 + I8X8 + I9X9 + I10X10 + ε 
where I10 is the coefficient for region.  In Column (4), we 
add the variable “Year,” which accounts for the specific 
effects of the study years using 2010 as the comparison.  
The regression equation is adjusted one final time to 
(5)    Y = I0 + I1X1 + I2X2 + I3X3 + I4X4 + I5X5 + I6X6 +  
         I7X7 + I8X8 + I9X9 + I10X10 + I11X11 + ε 
where I11 is the coefficient for year.  This final column is 
the most robust, as it accounts for three types of fixed 
effects that may affect endogeneity.  We find that, as the 
literature suggested, mother hemoglobin level, child 
weight-for-height percentile, no education, poor, and 
residence all have statistically significant effects on a 
child’s likelihood of being moderately or severely 
anemic.  We also find that a child’s age is statistically 
significant, though it was not mentioned in the literature 
reviewed.  This prepares us for our DID regression, 
where we include these variables as protections against 
endogeneity having confirmed their relevance. 
5.2. DID regressions 
We performed the DID regression three times, each 
time adding a level of control against endogeneity.  Table 
6 shows the coefficients when Y is the combined binary 
variable for moderate or severe anemia.  Column (1) 
shows the coefficients of for the binary variables “Treat” 
and “After”, which correspond to T and t, respectively.  
This first regression uses the basic DID equation 
(1)   Y= β0 + β1(t) + β2(T) + β3(t × T) + ε 
where β3 is the variable of interest and includes no 
controls for fixed effects, making these values subject to 
endogeneity concerns.  In Column (2), we add 
independent variables I1 through I8.  We include child 
birth order and family size for consistency, even though 
they were not found to be statistically significant at the 
95% confidence interval.  The DID regression equation 
is thus adjusted to 
(6)   Y= β0 + β1(t) + β2(T) + β3(t × T) + I1X1 + I2X2 + I3X3  
       + I4X4 + I5X5 + I6X6 + I7X7 + I8X8 + ε 
Table 5: Determinants of anemia. 
  Dependent variable: Child has moderate or severe anemia 
 (1) (2) (3) (4) 
Child birth order .01178* .00804 -.00302 -.00273 
Family size .00077 .00082 .0005 .00026 
Mother hemoglobin level -.00313* -.00303* -.0022* -.00211* 
Child age -.00272* -.00257* -.00232* -.00231* 
Child weight-for-height percentile -.00001* -.00002* -.00001* -.00001* 
No education .05916* .0302* .02304* .02563* 
Poor .05011* .05347* .04569* .04424* 
Residence -.00482 .00484 .02689* .0288* 
     
Observations     
Country fixed effects No Yes Yes Yes 
Region fixed effects No No Yes Yes 
Year fixed effects No No No Yes 
Notes: Standard errors clustered at the DHS clustering level. Asterisk (*) indicates statistical significance at the 95% confidence interval. 
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In Column (3), we add the discrete variable Region to 
account for fixed effects.  The DID regression equation 
is adjusted for a final time to 
(7)   Y= β0 + β1(t) + β2(T) + β3(t × T) + I1X1 + I2X2 + I3X3  
       + I4X4 + I5X5 + I6X6 + I7X7 + I8X8 + I10X10 + ε 
This final column is the most robust.  Results were 
similar when DID regressions were performed for the 
dependent variables Child Severe Anemia and Child 
Moderate anemia, though more dramatic in the latter.  
The last value in the third column suggests that an 
Ethiopian child post-DTAA had a .03478 greater 
probability of being anemic than a Rwandan child post-
DTAA.  Contrary to our primary hypothesis, the results 
in Table 4 show a strong positive correlation between the 
post-DTAA time period and probability of moderate and 
severe anemia.  Despite this correlation, a number of 
concerns prevent an interpretation of this relationship as 
causal.  The results may only be declared inconclusive. 
6. Discussion 
Our results may be uncertain for a variety of reasons 
including violations of statistical assumptions and or 
local conditions.  These factors introduce both positive 
and negative bias, obscuring our final outputs. 
6.1. Violations of statistical assumptions 
Our statistical assumptions described in section 
4.4.1. may not have been met by our quasi-experimental 
design, introducing bias to both our OLS and DID 
regressions.  Our concerns are consistent with empirical 
challenges faced by similarly-designed studies. 
 
6.1.1. Reverse causality and omitted variables 
Our OLS regressions may violate assumptions E(ε) 
= 0 and Cov (x, ε) = 0.  The former is challenged by 
potential reverse causality.  Horton & Ross find that 
anemia may affect metabolic systems, therefore 
affecting a child’s weight-to-height percentile (2003, 
p.63).  As a risk factor for infant mortality and delayed 
development, anemia may also contribute to poverty via 
additional direct and indirect healthcare expenditures 
(Van Ejik et al., 2007 as cited in Schady, 2012, p.887; 
Horton & Ross, 2003, p.53; Alzácar, 2012, p.49). 
Omitted variables may violate both assumptions 
E(ε) = 0 and Cov (x, ε) = 0 and introduce positive bias.  
There are likely several determinants of child moderate 
or severe anemia that will naturally be correlated with 
our other independent variables, such as nutritional 
intake (Acemoglu, Johnson, & Robinson, 2001, p.1379; 
Ejigu, Wencheko, & Berhane, 2018, p.13).  Other 
relevant variables may include instinal worm infection 
and malaria (Bobonis, Miguel, & Puri-Sharma, 2006, 
p.4; Ejigu, Wencheko, & Berhane, 2018, p.13; White, 
2018, p.1).  Omission of potentially correlated variables 
was cited as a weakness of Ejigu, Wenchecko, & 
Berhane’s regression model (2018, p.13). 
6.1.2. Parallel trends assumption 
Recall that DID regressions require the parallel 
trends assumption, wherein changes in the treatment 
group over time are expected to be the same as the 
control group if no treatment were administered.  This 
may be violated by pre-treatment trends differences, 
extraneous events, and or irrelevance of variables of 
interest.  According to professor of economics David 
Albouy, “the failure of the parallel trend assumption may 
Table 6: 2011 Ethiopian-Indian DTAA effects. 
         Dependent variable: Child has moderate or severe anemia 



















    
Observations    
Independent variables I1 through I8 No Yes Yes 
Region fixed effects No No Yes 
Notes: Standard errors clustered at the DHS clustering level and shown in parentheses. Asterisk (*) indicates statistical significance at the 95% 
confidence interval. 
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in fact be a relatively common problem in many program 
evaluation studies” (n.d., p.1). 
6.1.2.1. Pre-treatment trends differences 
The parallel trends assumption suggests that “the 
untreated units provide the appropriate counterfactual of 
the trend that the treated units would have followed if 
they had not been treated – that is, that the two groups 
would have had parallel trends” (McKenzie, 2020).  
While the two groups do not have to be similar in 
absolute terms, their changes over time must be 
comparable.  This implies developmental similarities 
between the two groups, including external factors like 
environmental, social, and economic conditions. 
As shown in Figure A6, the parallel trends 
assumption appears to hold in the prevalence of anemia 
among children under five for Ethiopia and Rwanda.  
The assumption holds because both countries show a 
downward trend in prevalence, but it’s important to note 
that Ethiopia’s absolute rates are considerably higher 
(World Bank, 2016).  According to a 2019 study by 
Kahn-Lane and Lang, “DID will generally be more 
plausible if the treatment and control groups are similar 
in levels to begin with, not just in trends” (McKenzie, 
2020). 
Figures A7, A8, and A9 show determinants of 
anemia for which the parallel trends assumption does not 
hold due to differences before the study period (pre-
2010).  Malaria, a major cause of anemia, was highly 
variable in both countries in the early 2000s (White, 
2018; World Bank, 2018a).   Urbanization trends and 
persistence to the last grade of primary school were also 
dissimilar, and were found in both the literature and our 
OLS regressions to be correlated with anemia (World 
Bank, 2019c; World Bank, 2018b; Worku, Tesema, & 
Teshale, 2020, p.2; Ejigu, Wencheko, & Berhane, 2018, 
p.1).  Failure of the parallel trends assumption for these 
correlates may bias the DID regression for anemia itself. 
6.1.2.2. Extraneous events 
Our study may violate the parallel trends assumption 
if unexpected measures were introduced in either the 
treatment or control country during the period of 
observation. 
For example, the 2011 Kigali Special Economic 
Zone (KSEZ) Law created a regulatory body to oversee 
the development and promotion of SEZs in Rwanda 
(Saunders, 2019).  The KSEZ offers special access to 
infrastructure, tax incentives, customs exemptions, and 
preferential regulatory treatment that is attractive to 
industry, especially among the Chinese (Steenbergen & 
Javorcik, 2017, p.2; Saunders, 2019).  This has been 
made possible in part by the government’s proper 
handling of foreign aid, 58% of which was channeled 
through the national government by 2010 compared to 
just 20% in most post-conflict countries (Savchuk, 
2014).  These business environment improvements and 
subsequent industrial growth could have increased per 
capita income in Rwanda, improving household wealth 
that is negatively correlated with anemia (Ejigu, 
Wencheko, & Berhane, 2018, p.1).  This would 
introduce negative bias into our model.  It appears that 
the SEZs did not result in local pharmaceutical 
manufacturing specifically, since as of 2018, there were 
still no local producers in Rwanda (USDOC, 2018). 
In Ethiopia, ongoing conflicts with neighbors 
Eritrea and Somalia may have contributed to poverty, 
food scarcity, and other negative public health 
consequences.  Though formally ended with the signing 
of the Algiers Peace Agreement in 2000, the Ethiopian-
Eritrean border dispute remains hostile due to continued 
support of rebel groups as proxies (Gebreluel & 
Tronvoll, 2013).  In 2013, Eritrea was reported by the 
UN to have paid political agents linked to Islamist 
militants to influence the Somali government, whom 
Ethiopia had sent troops to support (Maasho, 2013).  
Children living in affected regions may suffer health 
impacts from instability including lower height-for-age 
and poor nutritional status, which would introduce 
negative bias into our model (Barker, 1998 as cited in 
Arkesh, Lucchetti, & Thirumurthy, 2011, p. 2).  It is 
therefore possible that the 2011 Ethiopian-Indian DTAA 
did result in greater local pharmaceutical manufacturing, 
but that the benefits of access where offset by larger 
events with negative health impacts. 
6.1.2.3. Drug access not a primary determinant of 
anemia 
It may be that the price of drugs to treat anemia is 
much less important than the lifestyle conditions that 
cause it.  If access to haematinics is not a primary 
determinant of anemia, then any local production effects 
of the DTAA would be irrelevant.  We assume that the 
DTAA benefits consumers via improved access from 
local production.  If the DTAA were to have no effect, 
then our results would purely reflect extraneous events. 
Though Chaudhuri et al. (2010), Mujinja et al. 
(2014), and Ewen et al. (2017) found that local 
production improved rural and low-income access to 
essential medicines, it may still be true that such access 
is not a primary determinant of anemia.  Although 
wealth, for example, which is correlated with anemia and 
is a proxy for purchasing power (suggesting price 
sensitivity), wealth is also likely correlated with 
nutritional status, education, residence, and access to 
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healthcare.  These may be more significant than access 
and are not affected by the DTAA.   
Residence and access to healthcare, for instance, are 
particularly important for anemia.  Our OLS regressions 
show that the Affar region, for example, where 91% of 
the population is rural, is significantly correlated with a 
higher probability of moderate anemia (Ethiopia Sheep 
and Goat Productivity Improvement Program [ESGPIP], 
n.d.).  Since the 1990s, the region has experienced a 
major drought every two to three years, affecting access 
to nutrition (ESGPIP, n.d.).  Similar issues are seen in 
the Somali region and Dire Dawa administrative city 
(UNICEF, 2019; Fuller, 2019).  Distance to health 
facilities is higher in rural areas and is recognized as a 
critical barrier to maternal care and iron supplementation 
uptake (Sabine & Oona, 2009 as cited in Manang, 2019; 
Simuyemba et al., 2020, p.1).  Because anemia is 
especially prevalent among pregnant women and may be 
passed to the child, maternal care is critical to anemia 
prevention (Schady, 2013, p.887; Monterrosa et al., 
2018, p.1). Though the development of industry may 
increase per capita income over time, the FDI resulting 
from the growth of the pharmaceutical sector specifically 
is unlikely to make significant impacts on population 
distributions between rural and urban areas.  In other 
words, local pharmaceutical manufacturing may only 
address some pieces of the puzzle, and not necessarily 
the most important ones. 
6.1.2.4. DTAA has no effect on FDI 
Our study relies on the assumption that Hypothesis 
(a), tax incentives effectively induce greater foreign 
direct investment in East Africa, including 
pharmaceutical production, is true based on the 
literature.  However, there are also several studies that 
have found this claim to be false.  Again, if the DTAA 
were to have no effect, our results would purely reflect 
extraneous events. 
A 2007 study by Neumeyer across developing 
countries found that DTAAs only led to greater FDI 
among middle-income countries, not low-income 
countries like Ethiopia and Rwanda.  A 2015 study by 
Shah & Qayyum similarly found that DTAAs have no 
effect on FDI.  Rather, the study explains, “market size, 
development level, trade openness, and human capital” 
are stronger determinants of FDI (Shah & Qayyum, 
2015, p.1).  The draw of double taxation avoidance may 
be offset by the deterrent of limited opportunity for tax 
evasion (Shah & Qayyum, 2015, p.1).  A 2006 study by 
Egger et al. even found that DTAAs have a negative 
effect on FDI, which might explain Rwanda’s favorable 
performance in our DID regression except for our 
knowledge that Rwanda has (and had for the majority of 
the study period) no local pharmaceutical production 
(USDOC, 2018).  Our assumption that the 2011 
Ethiopian-Indian DTAA would be effective in inducing 
FDI may have been premature given the inconclusively 
of the literature. 
6.2. Local conditions 
It may also be that the Ethiopian-Indian DTAA did 
result in greater local pharmaceutical manufacturing, but 
that comparative market immaturity in Ethiopia as 
compared to Rwanda prevented the realization of 
benefits presented in the literature. 
6.2.1. Economies of scale 
For local pharmaceutical production to improve 
access to medications via lower prices, firms must have 
access to economies of scale (Kaplan & Laing, 2005, 
p.7).  Firms in sub-Saharan Africa are disadvantaged by 
higher input, logistics, and financing costs which can be 
offset only by volume (Chaudhuri & West, 2014, p.24).  
A 2004 modelling study by Guimier, Lee, & Grupper 
confirms the sensitivity of domestic manufacturing to 
market share. 
The Rwandan pharmaceutical market is 
consolidated among just two types of players, 
government procurement agencies and private importers 
(USAID, 2016, p.1).  With greater market share, the 
government may therefore be able to negotiate better 
pricing in international tenders, which could translate 
into better access via lower prices or better availability 
for patients.  By contrast, Ethiopia’s pharmaceutical 
market is more liberalized and heterogenous, preventing 
the consolidation of market share necessary for 
economies of scale. 
6.2.2. Regulatory environment 
Although Ethiopia’s regulatory budget is quite large 
for a developing country, Rwandan regulatory efforts 
may be more efficient and effective (Conway et al., 
2019, p.7). 
6.2.2.1. Protections against counterfeit drugs 
Robust protections against counterfeit drugs in 
Rwanda may boost patient confidence, encouraging 
individuals to visit health care facilities.  A 2013 study 
by Binagwaho et al. found that among the 17 countries 
observed, “Rwanda was the only African nation whose 
samples did not include any falsified products” (p.1).  A 
2008 study by Nsimba found that counterfeit drugs in 
developing countries reduce patient confidence in 
healthcare professionals and or modern medicine.  
Greater confidence in healthcare may lead Rwandans to 
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attend health facilities more often, allowing them to 
know their health status and medicate as necessary. 
6.2.2.2. National insurance programs 
Universal health coverage is more developed in 
Rwanda than in Ethiopia.  Though Ethiopia has made 
efforts to improve the national insurance system, 
introducing pilot programs in 13 districts in 2012, full 
implementation is still in its intermediate stages 
(USAID, n.d.).  By contrast, Rwanda’s community-
based health systems were internationally recognized as 
early as 2014 as a model of success in achieving 
universal health coverage (Management Sciences for 
Health [MSH], 2016; MSH, 2014).  Between 2003 and 
2013, health insurance coverage expanded from just 7% 
of the target population to 74% (MSH, 2016).  Benefits 
include protections against out-of-pocket costs and 
“better access to drugs” (MSH, 2016).  Like protections 
against counterfeit drugs, this insurance system may lead 
Rwandans to attend health facilities more often, allowing 
them to (a) know their health status and (b) afford 
relevant medicines. 
6.2.2.3. Intellectual property law 
As described in section 3.3.4., Rwanda is an outlier 
among African countries, having fully aligned its 
intellectual property law with that of TRIPS and other 
international conventions (Owoeye, 2014, p.215).  
Rwanda also actively exercises the benefits of the 
Paragraph 6 System – a TRIPS flexibility mechanism 
given legal status in 2005 (Kampf, 2015, p.2, 16).  The 
Paragraph 6 System provides a special type of 
compulsory license for WTO member states producing 
medicines for to meet the needs of other members 
(Kampf, 2015, p.4).  Importantly, however, the process 
“requires domestic action on the part of beneficiary 
countries to identify and communicate relevant needs for 
imports…[to] foreign producers” (Kampf, 2015, p.16).  
The system therefore effectively creates an international 
communication system for procurement, which may 
result in lower prices by expanding trade opportunities 
(Kampf, 2015, p.16).  While Ethiopia may be eligible to 
use this system as a low-income country, there is little 
evidence of it doing so in the literature. 
6.2.3. Infrastructure 
With a geographical area 41 times smaller than that 
of Ethiopia, Rwanda has an advantage in the 
development of infrastructure (CIA, 2021a; CIA, 
2021d).  Road coverage, airport construction, and other 
transportation infrastructure is a significantly smaller 
development task.  Because of its size, the “urban bias” 
in essential medicine distribution described by Mujinja 
et al. may be less of a barrier to access in Rwanda (2014, 
p.1). 
7. Conclusion 
Our primary empirical test, our DID regression, was 
inconclusive due to various concerns over statistical 
assumptions.  We can neither confirm nor reject our 
hypothesis that local pharmaceutical production as 
stimulated by the 2011 Ethiopian-Indian DTAA 
provides better access to essential drugs like 
haematinics.  Our empirical concerns suggest that the 
determinants of anemia in children under five are many 
and interrelated. 
7.1. Directions for future research 
Future research may attempt to confirm the 
assumption of Hypothesis (a).  Literature regarding the 
effects of DTAAs on FDI is inconclusive, suggesting 
positive, negative, and zero correlation.  There is also 
little research on the impact on pharmaceutical FDI 
specifically, which would be optimal for this study. 
Other improvements may include the addition of 
other relevant independent variables (see: 6.1.1. Reverse 
causality and omitted variables) or the selection of a 
more geographically similar comparison country (see: 
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Supplement B1. Production Variations 
As illustrated in Figure B1, production can be 
classified by (a) investment type; local or import (b) 
branding type; branded or generic and (c) production 
stage; straight ingredients, premix, bulk finished 
products, finished branded products.  This results in 
roughly 16 different scenarios, each of which have 
unique barriers to entry.  The specific determination of 
all 16 scenarios is beyond the scope of this thesis, though 
the three classifications are useful for understanding the 
types of production possible. 
SB1.1. Investment type 
Local African producers currently hold just 20% of 
the market (Ford, 2017, p.40).  Challenges to local 
production include donor preference for foreign 
products, lack of economies of scale, and insufficient 
infrastructure, among others (Ford, 2017, p.40; 
Chaudhuri & West, 2015, p.34; Holt et al., 2015, p.9).  
For MNCs, exporting is attractive as the lowest risk 
market entry mode.  For African governments and 
citizens, however, the higher costs of drugs due to 
logistics costs and branding strain budgets and foreign 
exchange reserves.  Dr. Mohammed Nuri, founder of 
Medtech Ethiopia, and Dr. Kambanda Rucweri, former 
director of Rwanda’s LABOPHAR, explains these 
challenges in Case Studies B1 and B2. 
Local production in sub-Saharan Africa can be 
subdivided into two groups: (a) indigenous firms and (b) 
arrangements with foreign MNCs.  The latter group can 
be further dissected into entry modes including 
contractual agreements, joint ventures, acquisitions, and 
wholly-owned subsidiaries (Gundelach & Hansen, 2020, 
p.179).  In all these cases, local capacity is limited to 
manufacturing after the import of active pharmaceutical 
ingredients (APIs), with the exception of South Africa 
(Lartey et al., 2018, p.3; Owoeye, 2014, p.215; USAID, 
2016, p.2). 
In most cases of local production, the primary 
concern is cost competitiveness (Chaudhuri & West, 
2015, p.24).  Manufacturing in Africa presents several 
cost disadvantages, including lower productivity from 
lack of skilled labor, high materials cost, machinery 
imports, high fuel and electricity prices, and high 
financing costs (Chaudhuri & West, 2015, p.24).  Critics 
of African production argue that the same amount of 
funding buys more medicine if imported (Chaudhuri & 
West, 2015, p.24).  Others say that cost disadvantages 
are normal for developing industries and, with proper 
government intervention, represent only short-term 
challenges (Chaudhuri & West, 2015, p.24). 
While African governments tackle long-term 
regulatory and economic reform, MNCs seeking first-
mover advantages can offset risk by choice of entry 
mode.  Market entry strategy can be partially explained 
by the resource-based view, which suggests firms 
attempt to establish long-term competitive advantage 
through costly-to-copy resources (Gundelach & Hansen, 
2020, p.176; Verbeke, 2009 as cited in Addae & Addae, 
2013, p.29).  In the context of African pharmaceuticals, 
these resources may include local distribution channels, 
relationships with supporting industries, or insight on 
local demand (Gundelach & Hansen, 2020, p.176-177).  
These assets act as counterforces to the challenges of 
developing markets, such complex regulation, small 
purchasing power, and information scarcity (Gundelach 
& Hansen, 2020, p.176).  According to researchers I. Y. 
Addae and M. V. Addae, FDI may also be motived by 
“market imperfections such as rising labor costs and 
enables firms to grow and expand by accessing demand” 
(Calvet, 1981 as cited in Addae & Addae, 2013, p.28).  
Choice of entry mode is also determined by transaction 
costs, or the costs of bargaining, information, and 
enforcement of contracts, which are high in developing 
markets due to institutional voids (Gundelach & Hansen, 
2020, p.178; Khanna, Palepu, & Sinha, 2005, p.1). 
In the case of high transaction costs and low firm 
resources, an MNC is likely to choose a less intensive, 
contractual entry mode like using agents, distributors, or 
licensing arrangements (Gundelach & Hansen, 2020, 
p.180).  Agents and distributors help the MNC 
understand institutional barriers and local networks 
(Gundelach & Hansen, 2020, p.180; Addae & Addae, 
2013, p.33).  In licensing arrangements, an MNC 
contracts with local firms to produce proprietary 
products in exchange for a fee.  These options are 
relatively inexpensive and avoid the risk associated with 
major FDI (Anderson & Gatignon, 1986; Hennart, 1989; 
Pan & Tse, 2000 as cited in Addae & Addae, 2013, p.35.  
However, reliance on a foreign partner presents risk of 
opportunism, which may lead MNCs to eventually take 
equity stakes in their partners, creating joint ventures 
(Gundelach & Hansen, 2020, p.180). 
 In the case of high transaction costs and high firm 
resources, an MNC may acquire local firms or establish 
local subsidiaries (Gundelach & Hansen, 2020, p.180).  
These options require that MNCs have “long-term 
internationalization experience in similar regions and 
continued and robust engagement by the firm 
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management” (Gundelach & Hansen, 2020, p.180).  
Following the economic liberalization of the 1990s, 
international acquisitions and joint ventures became 
more popular (Boatend & Glaister, 2003 and Dadzie & 
Owusu, 2015 as cited in Oguji & Owusu, 2021, p.6).  
Case Studies B2 and B3 offer snapshots of joint ventures 
in Ethiopia and Rwanda, respectively.  Between 2005 
and 2014, the total value of acquisitions into Africa 
doubled to reach $79 billion compared to the previous 
decade – a trend that experts predict will continue as 
MNCs from BRIC countries continue to target Africa’s 
growing consumer base (UNCTAD, 2015; Davies & 
Seigain, 2014; UNCTAD, 2017 as cited in Oguji & 
Owusu, 2021, p.6).  The lower the cultural distance 
between the MNC’s home and target countries, the lower 
the perceived risk, and thus the more likely the firm is to 
choose an equity-based entry mode (Wrona & 
Trapczynski, 2012, p.309).  According to researchers 
Bhaumik and Gelb, acquisitions are popular choices in 
fast-growing, fast-changing markets to secure first-
mover advantage (2005, p.10).  Conversely, in fast-
growing industries that promise long-term profitability, 
subsidiaries reduce agency and restructuring costs in the 
long run despite upfront investment (Bhaumik & Gelb, 
2005, p.10; Addae& Addae, 2013, p.33). 
The choice of entry mode has implications for the 
productivity of local firms via technology diffusion and 
competition (Bhaumik & Gelb, 2005, p.5).  In fact, by 
the end of the twentieth century, FDI surpassed trade as 
a primary driver of economic growth in emerging 
markets (Bhaumik & Gelb, 2005, p.6).  Technology 
diffusion increases with FDI (Bhaumik & Gelb, 2005, 
p.7).  However, in most cases, MNCs’ operations in 
developing countries represent small segments of their 
overall portfolio, “usually opting for products that 
are…in the low-technology downstream segments of 
their supply chain” (Bhaumik & Gelb, 2005, p.8).  
Despite the importance of choice of entry mode, many 
MNCs make investment decisions based simply on 
“senior managers’ personal experiences, family ties, gut 
feelings, or anecdotal evidence” (Khanna, Palepu, & 
Sinha, 2005, p.3; Oguji & Owusu, 2021, p.7).  
Incomplete data on emerging markets means that MNCs’ 
decisions are “not necessarily based on rational, factual 
premises” (Wrona & Trapczynski, 2012, p.306). 
In the case of sub-Saharan Africa specifically, the 
jury is still out on the merits of local production 
compared to importing.  Roughly 50% of the continent’s 
existing local capacity is underutilized (Chaudhuri & 
West, 2015, p.34).  Though some researchers suggest 
that local production could improve access via price 
reductions (Gebre-Mariam, Tahir, & Gebre-Amanuel, 
2016, p.65-66), others suggest that “these prices may still 
be relatively high compared to the paying capacity of the 
consumers” and would therefore produce no tangible 
effect (Chaudhuri & West, 2015, p.34).  The efficacy of 
investment type is likely dependent on country, entry 
mode, product type, and other factors.  These factors will 
be explored in in further detail in Case Studies B1 
through B4. 
SB1.2. Branding type 
Because drugs are only granted patent protection for 
20-25 years, much of which is lost during pre-market 
development, “developers of original medicines have 
sought to cover their research and development costs by 
maintaining high prices for their products” (Wrona & 
Trapczynski, 2012, p.298; Ford, 2017, p.40).  As a result, 
such products are often unaffordable for African patients 
(Ford, 2017, p.40).  However, many Indian companies 
produce generic versions of the same drugs that are 
available at a fraction of the cost (Ford, 2017, p.40).  
These medications are especially popular among 
international aid organizations (Ford, 2017, p.40). 
Local producers then fall into three categories: (a) 
indigenous firms (b) arrangements with foreign branded 
originators and (c) arrangements with foreign generics 
producers.  Sub-Saharan Africa has very few indigenous 
firms with research and development capacity, therefore 
such companies are likely to use compulsory licensing to 
produce generics.  Indian producers are leaders in the 
African market in both branded and generic options. 
SB1.3. Production stage 
Local African producers only engage in a limited 
range of the value chain due to a reliance on imported 
raw materials (Mohamed, 2018, p.8).  Almost all local 
producers are drug-product manufacturers, meaning they 
import APIs and formulate them into finished products 
(Conway et al., 2019, p.4; USAID, 2016, p.2).  
Production can thus take the following forms: (a) import 
APIs that are mixed and packaged by local 
manufacturers (b) import or produce premixes that are 
packaged by local manufacturers (c) import bulk 
finished products for local packaging and branding (d) 
import branded package products for local distribution 
(Monterrosa et al., 2018, p.1).  Researcher and 
nutritionist Eva Monterrosa explains that “scenarios A 
and B require local manufacturing capacities for 
blending and mixing; scenario C is likely to be found in 
countries with lower manufacturing capabilities; and 
scenario D in countries with no capacity or small 
consumer markets” (2018, p.2).  Production stage is 
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important for its effect on value-added taxes. 
MNCs must consider the benefits of entry modes 




Case Study B1 
EPHARM, Ethiopia 
In 1964, the Ethiopian Pharmaceuticals 
Manufacturing Share Company was established as the 
first pharmaceutical producer in the country (“Ethiopia: 
EPHARM, 2020).  Then known as Ethiopian dmg 
Manufacturing Shack (EDMSC), the company was 
jointly controlled by British company Smith & Nephew 
and the Imperial Ethiopian Government (EPHARM, 
n.d.).  Having reported significant losses, in 1970, the 
government called for international bidders and signed 
an agreement with Israel’s TEV, the former retaining a 
51% stake (EPHARM, n.d.).  The company was renamed 
to EPHARM and began to turn a profit (EPHARM, n.d.).  
Though nationalized following the popular revolution of 
1974, it was re-privatized in 1994 and purchased by 
Medtech Ethiopia in 2014 (EPHARM, n.d.).  It is located 
in Addis Ababa and has eight production lines, including 
tablets, capsules, sachets, and liquids (EPHARM, n.d.). 
With over 50 years of experience in the Ethiopian 
market and an exceptionally wide range of products, 
EPHARM is considered an industry leader (EPHARM, 
n.d.).  With plans to develop another 40,000 square meter 
GMP-compliant factory and begin exporting to 
Somaliland and South Sudan, the company aims to rank 
among the top three African pharmaceutical companies 
by 2025 (EPHARM, n.d; “Ethiopia: EPHARM,” 2020.). 
However, Dr. Mohammed Nuri, Medtech’s founder 
and chief executive, believes there is still far to go.  
According to him, although “there is significant change 
in the pharmaceutical industry’s landscape between now 
and five years ago [and] the government has now given 
huge attention to the sector…the country’s 
pharmaceutical companies barely cover 15% of local 
demand” (Taye, 2016).  Besides, local industry is still 
reliant on imports for 99% of all inputs (Mulupi, 2015).  
Dr. Nuri also laments the “lack of access to sufficient 
foreign exchange” and the reliance on ground transport 
from the port of Djibouti, which takes almost two days 
(Taye, 2016; Mulupi, 2015). 
Looking forward, Dr. Nuri welcomes competition: 
“There are some Indian companies that are coming.  
Branded multinationals are also on the way.  There is a 
huge gap, so there will be room for all of us.  Ethiopia 
needs more drug manufacturers” (Mulupi, 2015).  
Contrary to pharmaceutical giants in the West, local 
producers in Ethiopia are eager for price-lowering 
competition to help build infrastructure and achieve 
economies of scale.  Their attitude is simultaneously 
collectivist and free market-based, not just at the policy 
level, but at the individual firm level. 
Case Study B2 
LABOPHAR, Rwanda 
Established in 1981, the Pharmaceutical Laboratory 
of Rwanda used to be the sole drug manufacturer in the 
country (Hakizimana, 2021).  In 2011, the former 
Procurement Agency for Medical Equipment, Drugs, 
and Supplies (CAMERWA) merged with LABOPHAR 
to create the Medical Procurement and Production 
Division (MPPD) of the Rwanda Biomedical Center 
(RBC) (Hakizimana, 2021).  According to a 2018 report 
by the Auditor General, the medical production unit 
became inoperative in 2013 (Hazikimana, 2021).  
Because MPPD failed to perform strategic business and 
annual planning after the merger, its essential medicine 
production fell to 0% (Hazikimana, 2021).  
Consequently, “essential medicines that were produced 
by MPPD…experience recurrent stock out” and raw 
materials worth over RWF 350 million are either idle or 
expired (Hakizimana, 2021). 
Before the shutdown, though, LABOPHAR was 
GMP-compliant and enjoyed access to skilled personnel 
from the neighboring National University of Rwanda 
(USAID, 2016, p.1).  The factory produced both tablets 
and serums sold across Rwanda, the DRC, Burundi, and 
Tanzania (“LABOPHAR eyes,” 2010).  In 2010, then-
director Dr. Kambanda Rucweri expressed the need for 
government support, saying “we are currently facing the 
problem of budgetary constraints because we have to 
largely depend on the sales” (“LABOPHAR eyes,” 
2010).  Struggling to gain market share both locally and 
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internationally, LABOPHAR was directly engaged in 
creating and educating its market, advocating for the 
safety and usage of local drugs over imports 
(“LABOPHAR eyes,” 2010). 
Frustration over LABOPHAR’s failure is expressed 
at the national level by members of parliament, who 
support local manufacturing as good for the economy.  
According to MP Jeanne d’Arc Uwimanimpaye, the 
government’s role is to invest in those areas that private 
investors are reluctant to due to high barriers to entry 
(Hakizimana, 2021).  In the case of pharmaceuticals, the 
draw is even greater, as the industry is highly profitable 
(Hazikimana, 2021).  Similarly, MP Christine 
Bakundufite complained “why can’t we back 
LABOPHAR instead of just criticizing it” (Hazikimana, 
2021). 
In 2019, RBC Director-General Dr. Sabin 
Nsanzimana told lawmakers that despite talks with over 
ten investors scouted for overtaking LABOPHAR, 
private sector interest was limited due to the lab’s old 
equipment, small land, and non-GMP compliant 
facilities (Hakizimana, 2021).  Other issues include poor 
asset and equipment management and embezzlement, 
which caused government losses of over RWF 5.8 billion 
between 2013 and 2018 (Sabiiti, 2020). 
In response to shortages, the government is now in 
the process of introducing the Rwanda Medical Supply 
(RMS) to replace MPPD, which will be authorized to 
import directly from international manufacturers 
(Uwizeyimana et al., 2021, p.3).  
Case Study B3 
Cadila Pharmaceuticals, Ethiopia 
In 2007, owning 57% and 43% respectively, Cadila 
Pharmaceuticals of India partnered with Almeta Impex 
PLC of Ethiopia to create Cadila Pharmaceuticals 
Ethiopia PLC (CPEL) (Gebre-Mariam, Tahir, and 
Gebre-Amanuel, 2016, p.68).  The venture was Cadila’s 
first overseas formulation manufacturing facility and 
was largely motivated by potential market size (“Cadila 
opens,” 2007; Gebre-Mariam, Tahir, & Gebre-Amanuel, 
2016, p.68).  The $10 million plan imported all 
machinery and raw materials from India, and now has 
capacity to manufacture 390 million tablets, 165 million 
capsules, and 1.44 million liters of liquid annually in its 
10,6000 square meter campus (Gebre-Mariam, Tahir, & 
Gebre-Amanuel, 2016, p.68; “Cadila pharma’s,” 2011).  
In 2011, the company earned a GMP certificate (Gebre-
Mariam, Tahir, & Gebre-Amanuel, 2016, p.68). 
The joint venture was celebrated by Ethiopian 
Minister of Trade and Industry Girma Birru as a 
“milestone in the relationship between India and 
Ethiopia” (“Cadila opens,” 2007).  Executive vice 
president of international business at Cadila 
Pharmaceuticals Mahidhwaj Sisodia explained the 
strategic partnership: 
While starting out, we had to deploy 
manpower from India….  But gradually we 
started building the local skills.  We have 
empowered local leadership and people to 
take over and lead operations.  The secret 
to our acceptance was that we always 
considered ourselves a local company by 
adapting their culture and values (Ruchika, 
2020). 
CEPL’s joint venture strategy is supported by 
USAID, which describes such entry modes as “catalysts 
for the development of the pharmaceutical industry in 
Africa” (2016, p.2).  The transfer of skills and 
technology is critical to the development of local 
capacity (USAID, 2016, p.2).  For the foreign partner, 
joint ventures offer a “localization of knowledge,” which 
is particularly important given that the “effectiveness 
and nature of formal and informal institutions” are both 
critically important and complex in developing countries 
(Gebre-Mariam, Tahir, & Gebre-Amanuel, 2016, p.66; 
North, 1990; Chen et al., 2017; Meyer et al., 2009; & 
Peng, 2014 as cited in Gundelach & Hansen, 2020, 
p.178).   
Case Study B4 
CSM Global Pharma 
In 2011, India’s Cadila Pharmaceutical Ltd planned 
a joint venture with American Holtzman Group to be 
named CSM Global Pharma (“$65M to be invested,” 
2011).  The new facility in Kigali would cost $65 million 
and have capacity for solids, liquids, biologicals, and 
even APIs (Das, 2013).  The plan was also celebrated for 
its expected job creation and technology diffusion (Das, 
2013; “$65M to be invested,” 2011).  With around 30% 
of imports into Rwanda being counterfeit, CSM was 
touted as a path to import independence by producing 
high quality drugs at competitive prices (“$65M to be 
invested,” 2011). 
However, after 2014, there is no available 
information on the company, suggesting its formation 










Factors Determining Local Production Capacity 
 
Source: Mohamed, 2018, p.26.  Supported by studies 
conducted by Chaudhuri & West, the International 
Trade Association, McKinsey & Company, and others. 
Supplement C1. Ethiopia Additional Information 
SC1.1. Historical background 
Ethiopia is located in East Africa and borders 
Djibouti, Kenya, Somalia, South Sudan, and Sudan.  
Though the Ethiopia-Somalia border is largely 
undefined, the country’s size is generally accepted to be 
just less than twice the size of Texas (CIA, 2021a).  
Figure C2 provides a map.  Ethiopia is the “oldest 
independent country in Africa and one of the oldest in 
the world,” having avoided colonization with the 
exception of a brief Italian occupation from 1936 
through 1941 (CIA, 2021a). 
In 1974, Ethiopia became a socialist state under a 
military junta, the Derg (CIA, 2021a).  The regime was 
overthrown in 1991 and replaced by a federal 
parliamentary republic, which adopted its constitution in 
1994 (CIA, 2021a).  The country is divided into “nine 
ethnically-based regional states and two self-governing 
administrations” and uses a civil law system (CIA, 
2021a). 
In 2012, Prime Minister Zenawi died in office and 
was replaced by Deputy Prime Minister Desalegn – “the 
first peaceful transition of power in decades” (CIA, 
2021a).  In 2018, following several years of popular 
protest, Desalegn resigned and Abiy Ahmed took office 
(CIA, 2021a). 
SC1.2. Economies of scale 
Local producers require large markets to achieve 
economies of scale, as manufacturing has high fixed 
costs in machinery, qualified personnel, and insurance, 
as well as other inputs.  Ethiopia’s sheer size – a 
population of over 100 million and the second most 
populous in Africa – makes it a large target market for 
medicines generally (CIA, 2021a).  According to 
Anteneh Senbeta, deputy commissioner for corporate 
affairs at the Ethiopian Investment Commission, 
Ethiopians spent $700 million annually on drugs as of 
2018 – a value expected to grow dramatically (Gebre, 
2018).  A 2017 study by Misganaw et al. in Ethiopia 
found that between 1990 and 2015, “non-communicable 
diseases were the leading causes of age-standardized 
mortality rates,” reflecting the shift towards NCDs 
(Misganaw et al., 2017, p.1).  For anemia specifically, 
despite a more than 50% reduction in IDA over the study 
period, as of 2016, 57% of Ethiopian children under five 
years of age “suffered from some degree of anemia 
(haemoglobin levels below 11 g/dl)” (Misganaw et al., 
2017, p.1; Central Statistical Agency [CSA] & ICF, 
2016, p.195).  24% of women and 15% of men were also 
found to be anemic (CSA & ICF, 2016, p.199).  
But many other factors combine to make an anemic 
individual a haematinic consumer.  Ethiopia has a low 
per capita GDP of just $2,221 as of 2019, roughly one-
third of India’s (CIA, 2021a; CIA, 2021c).  This makes 
consumers particularly price sensitive.  Moreover, 
anemic individuals may not know their health status, as 
physician density in Ethiopia is just 0.08 physicians per 
1,000 population (CIA, 2021a). 
A 2015 simulation study conducted by researchers 
Chaudhuri and West explored the feasibility of local 
production in Ghana given cost constraints.  It concludes 
that local manufacturing is feasible only if large markets 
are ensured through government cooperation (Chaudhuri 
& West, 2015, p.35).  Though not specific to Ethiopia, 
the report's principles still apply. 
According to the study, “if the international 
suppliers lose markets because of local production, they 
can and do retaliate by reducing their prices” (Chaudhuri 
& West, 2015, p.34).  Governments buy drugs in large 
quantities through competitive bidding processes, 
driving down prices that are annually reported in the 
WHO’s International Drug Price Indicator Guide 
(Chaudhuri & West, 2015, p.24).  These prices act as 
international reference prices and are considered the 
cheapest at which medicines can be bought or sold 
(Chaudhuri & West, 2015, p.34).  If local producers 
charge these prices, they become competitive with 
international producers and reduce prices for consumers 
(Chaudhuri & West, 2015, p.35).  So long as the 
international reference price is higher than the cost of 
production, local manufacturing is possible if the 
necessary market is secured (Chaudhuri & West, 2015, 
p.35).  In other words, local manufacturers will likely 
have lower profit margins due to higher input costs, but 
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government intervention can offset this loss with higher 
volume via import restrictions, public procurement 
regulations, or reimbursement under national insurance 
(Chaudhuri & West, 2015, p.36-37).   
Though it is unlikely that international suppliers 
would offer prices below the international reference 
prices, even if they did, local production does not 
become unviable unless “the imported price is higher 
than the local average variable cost per unit,” which is 
unlikely (Chaudhuri & West, 2015, p.35-36).  The size 
of the market is the most crucial determinant of 
feasibility. 
To some degree Ethiopia has already acknowledged 
this.  According to the International Trade 
Administration, the Ethiopian Pharmaceutical Supply 
Agency solicits imports through tender announcements 
“made accessible to all interested potential bidders, 
regardless of the nationality of the supplier or origin of 
the products” (2020a).  Drugs are also imported via 
tender by the Ministry of Health, PHARMID, non-
governmental organizations, and private importers 
(Embassy of the Federal Democratic Republic of 
Ethiopia [EFDRE], 2015, p.2).   
Though some concerns have been raised regarding 
the lack of transparency in the bid evaluation processes, 
this tender system generally represents an attempt at non-
discriminatory procurement (ITA, 2020a).  This process 
lowers drugs prices compared to monopolies or long-
term contracts.  However, advocates of local production 
argue that, contrary to the free-market economics 
popularized in Africa in the 1990s, the government 
should take sides - an initial non-competitive decision to 
favor local production will actually enhance long-term 
competition at home by opening markets for domestic 
manufacturing. 
At the front end of the supply chain, Ethiopia has 
implemented incentives for local production including 
tax breaks and customs exemptions (“Local pharma,” 
n.d.). Between 2016 and 2018 alone, foreign companies 
invested $213 million into the industry “lured by 
government offers to facilitate exports and allow 
companies to repatriate profits” (Gebre, 2018).  For India 
specifically, one such incentive is the 2011 DTAA with 
reduced rates for dividends, interest, royalties, and fees 
for technical services. 
Other government interventions include incentives 
under the Industrial Development Strategy, which 
identifies the private sector as the “engine” of the 
manufacturing sector’s growth (EFDRE, 2015, p.1).  The 
pharmaceutical industry is given priority as a sub-sector, 
with incentives to produce “products that substitute for 
imported products and also supply export markets” 
(EFDRE, 2015, p.1). Local manufacturing helps correct 
the country’s trade deficit by a) reducing imports and b) 
potentially increasing exports.  Production registration 
time has been reduced to a month for local 
manufacturers, and if the firm exports 50% of their 
products, they are also eligible for an income tax 
exemption for five years (“Local pharma,” n.d.).   
Ethiopia’s membership in the Common Market for 
Eastern and Southern Africa (COMESA) offers 
preferential tariffs among 19 member countries, and 
proximity to the Middle East also offers potential trading 
partners (EFDRE, 2015, p.4).  In 2016, Ethiopia joined 
the African Trade Insurance Agency, which covers 
political risk for international investors and thus further 
supports FDI (ITA, 2020a). 
Besides sufficient medical demand, to reach 
economies of scale, local manufacturing requires 
government assistance.  This cooperation appears to 
have started with GOE investment incentives. 
SC1.3. Regulatory environment 
Ethiopia’s planned economy features significant 
government involvement throughout the supply chain.  
Under the 1994 constitution, the state owns all land and 
leases to tenants, resulting in corrupt and poorly 
regulated property rights, especially in urban areas like 
Addis Ababa (CIA, 2021a).  State ownership of key 
industries, including telecommunications, banking, and 
energy further constrain market growth (CIA, 2021a; 
ITA, 2020a).  In the 1980s and 1990s, following global 
trends of neoliberalism, Ethiopia began liberalizing 
through privatization (Rodrik, 2000, p.4).  By the early 
2000s, however, the “institutional underpinnings of 
market economies” were revealed through the 
foreclosure of four pharmaceutical manufacturers unable 
to compete against unregulated, substandard drugs 
(Rodrik, 2000, p.4; Gebre-Mariam, Tahir, & Gebre-
Amanuel, 2016, p.67).  The Ethiopian government thus 
began a period of reform to secure property rights, 
reduce fraud and anti-competitive behavior, and enforce 
corruption legislation (Rodrik, 2000, p.4).  In the absence 
of a pan-African regulatory body, individual efforts by 
Ethiopian agencies have resulted in a fragmented and 
highly complex web of agencies, initiatives, and law 
(Lartey et al., 2018, p.6).  For this reason, foreign 
producers often seek local partnerships to tap into 
regulatory expertise (Lartey et al., 2018, p.6). 
SC1.3.1. Players and programs 
Ethiopian regulators cover areas such as drug 
registration, taxes, and investment incentives – all of 
which affect FDI decisions.  In 2009, the African 
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Medicines Regulatory Harmonization (AMRH) was 
launched as part of the Pharmaceutical Manufacturing 
Plan for Africa to standardize the capacities of national 
medical regulatory authorities (Lartey et al., 2018, p.6; 
Kaufman et al., 2021).  Among these capacities were 
drug registration, variation of which often prevents 
manufacturers from registering products outside their 
countries of operation (Lartey et al., 2018, p.5-6).  This 
limits local manufacturing and therefore not only acts as 
a “barrier to access but also constrains market size” 
(Lartey et al., 2018, p.5).  In 2015, the AMRH was 
transitioned into a continental regulatory authority called 
the African Medicines Agency (Lartey et al., 2018, p.7). 
The government’s commitment to “reducing delays 
in product registration, ferreting out counterfeit drugs, 
and pushing manufacturers to meet standards required 
for exports” is also seen in reforms of the Food, 
Medicine, and Healthcare Administration and Control 
Authority (FMHACA), the Ethiopian Food and Drug 
Administration (EFDA), and the Ethiopian 
Pharmaceutical Supply Agency (EPSA) (Conway et al., 
2019, p.7; ITA, 2020a).  FMHACA and EFDA share 
“regulatory oversight for the registration, importation, 
and quality of medicines,” while “EPSA is the public 
procurement agency responsible for purchasing 
pharmaceuticals” (ITA, 2020a).  FMHACA is also offers 
local investment incentives, promising proprietary 
registration for locally-manufactured products (EFDRE, 
2015, p.8). 
Other local investment incentives include the 
Pharmaceutical Fund and Supply Agency (PFSA), which 
offers “30% advance payment for the purchase of [local] 
products won through national bidding and 25% price 
preference when local manufacturers participate in 
international bids” (Gebre-Mariam, Tahir, & Gebre-
Amanuel, 2016, p.72).  To attract FDI, the Development 
Bank of Ethiopia offers up to 70% of the investment 
capital for new pharmaceutical investments, 7.5% 
interest rates with long-term repayment horizons, 
customs duty privileges for capital goods, and tax 
holiday privileges, among other incentives (EIC, 2014 as 
cited in Gebre-Mariam, Tahir, Gebre-Amanuel, 2016, 
p.78).  GOE’s national policies have “been historically 
encapsulated in the…Growth and Transformation Plan 
(GTP),” which “lays out a plan for dramatic structural 
transformation, shifting from an agrarian economy to 
one more geared towards manufacturing and services” 
(ITA, 2020a).  At the international level, the formation 
of the Federation of African Pharmaceutical 
Manufacturers Associations (FAPMA) in 2013 
represented regional coordination on industry growth 
and contributed to the development of the 
Pharmaceutical Manufacturing Plan for Africa – 
Business Plan (PMPA-BP), a WHO-sponsored 
development framework (Lartey et al., 2018, p.7-8).   
While the coordination failures of the late 1990s 
“make it clear that strategic government interventions 
may often be required to get out of low-level traps and 
elicit desirable private investment responses,” the 
overlapping authority of private and public local, 
national, regional, and international players frustrates 
efforts at cohesive policy reform (Rodrik, 2000, p.7).  
This is seen again in Ethiopian tax law.  The East African 
Community removed duties on finished pharmaceutical 
products around 2010, but import duties have remained 
on raw materials, increasing prices for local producers 
(Ford, 2017, p.41).  Local production requires the import 
of raw materials and packaging, since Ethiopian capacity 
only currently exists at the secondary level (Lartey et al., 
2018, p.p.5).  To recover local producers lost market 
share, the government has implemented a wide range of 
other investment incentives, including preferential 
treatment in government procurement and DTAAs with 
key investors (Ford, 2017, p.41).  While perhaps a step 
in the right direction, the incentives remain piecemeal. 
SC1.3.2. Good manufacturing practice (GMP) 
The dearth of coordination is particularly evident in 
efforts to attain international GMP compliance.  
According to law firm Gowling WLG, specialists in 
African healthcare, GMP compliance “enables 
domestically manufactured pharmaceuticals to be traded 
in confidence between countries,” but implementation 
“requires the alignment of domestic policies across 
various government departments such as health, 
commerce, trade, and industry” (Ford, 2017, p.41).  
GMP standards cover all components of the production 
process from starting materials to labor (Chaudhuri & 
West, 2015, p.25).  Most African countries, Ethiopia 
included, “lack the facilities, equipment, analytical 
instrumentation, and the human capital…to attain and 
maintain compliance” (Lartey et al., 2018, p.4).  
Compliance is also costly – GMP equipment is often 
custom designed and imported with long lead times and 
upfront payments (Lartey et al., 2018, p.8).  But non-
compliance is also costly – local manufacturers who do 
not meet GMP guidelines have limited export markets 
and suffer from weaker reputation. 
SC1.3.3. Recent changes 
Despite continued challenges with bureaucracy and 
customs clearance times, according to McKinsey 
researchers Conway et al., “Ethiopia is investing ahead 
of the curve in regulatory capacity” (ITA, 2020a; 
Conway et al., 2019, p.7).  With a regulatory budget of 
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$6.6 million, Ethiopia enjoys a higher regulatory budget 
to market value ratio than Brazil, Russia, and Turkey 
(Conway et al., 2019, p.7).  In 2019, Prime Minister 
Ahmed furthered liberalizing reform by launching the 
Home Grown Economic Reform Agenda, which 
encourages FDI (ITA, 2020a).  Ahmed has also formed 
an interministerial committee to improve the country’s 
Ease of Doing Business ranking (ITA, 2020a).  Ethiopia 
could perhaps learn from South Africa, whose Medicines 
and Related Substances Control Amendment Act 
requires pharmacists to offer generic alternatives to 
patients when available, representing government 
support of the local generic market and ultimately 
lowering prices for consumers (NAPM, 2009, p.138-
139).  Since the Keynesianism of the 1990s, Ethiopia has 
“come to a better understanding of the reality that 
capitalist economies are not necessarily self-stabilizing,” 
and that a “mix of state and market, laissez faire and 
intervention” is preferential for healthy domestic 
competition (Rodrik, 2000, p.7, 10). 
SC1.4. Input materials 
As previously mentioned, pharmaceutical 
manufacturing in Ethiopia is currently limited to 
secondary stages, requiring the import of 95% of APIs 
and raw packaging materials (EFDRE, 2015, p.3; Gebre-
Mariam, Tahir, & Gebre-Amanuel, 2016, p.73).  These 
materials are the primarily variable costs of production, 
making Ethiopian industry sensitive to international 
prices (Chaudhuri & West, 2015, p.27).  Because African 
manufacturers are relatively small, “input materials are 
purchased in…quantities…at times too small to attract 
suppliers, and as a result manufacturers have no power 
to negotiate,” resulting in higher prices (Gebre-Mariam, 
Tahir, & Gebre-Amanuel, 2016, p.70).  As Chaudhuri & 
West’s simulation study explains, foreign reliance 
disadvantages African producers even if international 
competitors purchase APIs from the same source 
because of higher freight, insurance and working capital 
costs (2015, p.31).  African manufacturers must hold 
greater inventories for much the same reasons – creating 
additional costs in storage, insurance, and interest 
(Chaudhuri & West, 2015, p.31).   
Other input costs include machinery and technical 
assistance, which, because nearly always imported, 
represent significant barriers to entry for local firms 
given the lack of financing (to be discussed later) 
(Chaudhuri & West, 2015, p.31).  Electricity costs are 
also high in Ethiopia, as “demand continues to outpace 
supply” and “transmission lines and distribution 
facilities are inadequate” (ITA, 2020a).  Though Prime 
Minister Ahmed has supported projects to increase 
hydropower capacity, improvement is relatively slow 
due to state ownership and subsequent bureaucracy of 
the power distribution industry (CIA, 2021a).  Input, 
inventory, and other variable costs continue to be major 
barriers to profitable production. 
SC1.5. Capital investment and access to affordable 
finance 
Ethiopia suffers from an acute foreign exchange 
shortage resulting from excessive imports (ITA, 2020a).  
According to the International Trade Administration, the 
shortage limits “timely procurement of equipment, 
supplies, and pharmaceuticals” and may also lead to 
payment delays and exposure to price fluctuations 
(2020a; Gebre-Mariam, Tahir, Gebre-Amanuel, 2016, 
p.83).  In an attempt to improve the trade imbalance, in 
2017, the National Bank of Ethiopia devalued the birr by 
15% relative to the US dollar (CIA, 2021a; ITA, 2020a).  
Experts are divided on the projected effect of local 
manufacturing – some argue that local production could 
improve the deficit by reducing the need for imports and, 
eventually, contributing to exports.  Others, such as 
researchers Conway et al. of McKinsey & Company 
suggest that any improvements would amount to “less 
than 5% of Ethiopia’s projected foreign currency needs 
– not including the additional capital investments needed 
to build industrial parks and upgrade national regulators” 
(2019, p.8). 
The Ethiopian birr also suffers from high inflation, 
which has ranged from a high of 44% to a low of 6.63% 
over the 2008-2019 period (Pletcher, 2020).  For MNCs 
looking to expand into Ethiopia, this is particularly 
unfavorable, as profits will likely be converted to foreign 
currency.  Though 18 financial institutions and insurance 
companies exist in Ethiopia, only a fraction of surveyed 
Ethiopian firms obtained loans from domestic banks, 
citing “impossible” approval conditions (Hailu, 2017, 
p.31, 37).  
Ethiopia remains reliant on non-governmental 
organizations and international aid agencies to provide 
essential medicines, most of which are purchased abroad 
(Owoeye, 2014, p.215).  The United Nations Economic 
Commission for Africa (UNECA) awards over $200 
million in contracts annually using a centralized 
procurement system shared with the other 21 UN 
agencies located in Addis Ababa (ITA, 2020a).  In 2016, 
the Fund for African Pharmaceutical Development 
(FAP-D) was created by the African Union to “provide 
affordable financing to the industry in the form of low 
interest rate[s]” and long-term support (Lartey et al., 
2018, p.9).  All African Union member states are 
required to contribute funds (Lartey et al., 2018, p.9).  
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The program was created in the image of the Indian 
Credit Linked Capital Subsidy Scheme (CLCSS) that 
“enables small- and medium-sized pharmaceutical 
companies to access low interest rate, long-term 
government funds for upgrading, product promotion, 
and marketing” (Lartey et al., 2018, p.9).  The CLCSS is 
credited with positioning the Indian pharmaceutical 
sector as the third leading industry globally (Lartey et al., 
2018, p.9). 
Over the past several decades, Africa has received 
trillions of dollars in developmental aid despite evidence 
that such funding has long-term “negative effects on 
private investment in developing countries” (Moyo, 
2009; Herzer & Grimm, 2012; Selaya & Sunesen, 2012 
as cited in Addae & Addae, 2013, p.32-33).  By contrast, 
FDI is believed to be pathway to decreased dependence 
on foreign aid (Moto, 2009 as cited in Addae & Addae, 
2013, p.33). 
SC1.6. Other factors 
Among the factors necessary for local 
pharmaceutical manufacturing, labor, infrastructure, and 
technology are among the easiest to build, making them 
the lowest priority consideration for market entrants 
(Gebre, 2018). 
SC1.6.1. Skilled personnel 
Despite strong economic growth of an annual 
average of 10.3% in between 2006 and 2016, “Ethiopia 
remains one of the world’s poorest countries and low 
wages remain a big draw for investors” (Gebre, 2018).  
Even by Chinese standards, Ethiopian factory wages of 
$75 per month are quite low (Gebre, 2018).  Talent 
scarcity is particularly pronounced for those with 
industrial or managerial skills – only 7% of Africans 
hold tertiary degrees (Gebre-Mariam, Tahir, & Gebre-
Amanuel, 2016, p.70; Holt et al., 2015, p.7). Ethiopia’s 
school life expectancy is just nine years, and only 7.4% 
of the labor force works in industry (CIA, 2021a).  
Figure C3 shows the standard world map, while Figure 
C4 shows the same map adjusted for working 
pharmacists, highlighting scarcity in Africa. 
Wage costs are also a concern for local 
manufacturers attempting to maintain cost 
competitiveness.  In emerging markets, because “the 
market for casual labor is not as developed,” casual 
employees (in effect) become permanent employees and 
are therefore a fixed cost (Chaudhuri & West, 2015, 
p.32).  Low wages are offset by low productivity due to 
limited technical skills (Chaudhuri & West, 2015, p.32).  
Though average labor costs can be reduced through 
larger batch sizes, only larger firms can afford to produce 
at such volume (Chaudhuri & West, 2015, p.32). 
Although supporters of local production tout 
manufacturing as an opportunity for employment, critics 
suggest that any gains would be modest due to trends 
toward automation (Conway et al., 2019, p.8).  
Estimations of job creation are as low as a few thousand 
jobs, even including upstream and downstream effects 
(Conway et al., 2019, p.8).  Lack of skilled personnel 
contributes to the leanness of new plants, but it also 
contributes to the underutilization of existing facilities 
(Conway et al., 2019, p.8; Gebre-Mariam, Tahir, & 
Gebre-Amanuel, 2016, p.67) 
SC1.6.2. Infrastructure and capacity utilization 
Ethiopia’s population is largely rural, and a central 
mountain range creates infrastructure challenges for road 
construction (CIA, 2021a).  As of 2017, Ethiopia has but 
17 airports with paved runways and just one registered 
air carrier (CIA, 2021a).  It also has 659 kilometers of 
railway (2017) and 120,000 kilometers of roads (2018) 
(CIA, 2021a).  By contrast, France, which is half 
Ethiopia’s size with 40 million less citizens, has 294 
airports with paved runways (2017), 19 registered air 
carriers (2020), over 29,000 kilometers of railway 
(2014), and over 1 million kilometers of roads (2011) 
(CIA, 2021b). Ethiopia is landlocked and is reliant on the 
ports of Djibouti and Somalia for ocean freight (CIA, 
2021a). 
The lack of transportation infrastructure creates long 
lead times and generates higher communication, 
inventory, and insurance costs (Holt et al., 2015, p.9).  
End-to-end logistics providers, which “allow 
manufacturers to reduce costs,” are limited (Khanna, 
Pelepu, & Sinha, 2005, p.1).  According to a study by 
Bangalee & Suleman, the logistics fees of generic 
medicines represent a higher percentage of the single exit 
price (at which a pharmacy buys the drug from its 
suppliers) than for their originator branded counterparts 
(2015, p.9; NAPM, 2009, p.141).  Based on a logistics 
fee cap experiment in South Africa, branded 
manufacturers were suspected of offering distributors 
and wholesalers higher logistics fees as incentives for 
selection for distribution, therefore disrupting the 
competitive environment and driving up logistics costs 
across the industry (Bangalee & Suleman, 2015, p.2, 9). 
Capacity utilization is also an issue.  During the 
period 1995 to 2004, pharmaceutical manufacturers in 
Ethiopia operated at only 50% of installed capacity 
(Gebre-Mariam, Tahir, & Gebre-Amanuel, 2016, p.67).  
This figure improved from 2005 to 2014, reaching 79% 
in 2013 and reflecting a growing market for local 
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production (Gebre-Mariam, Tahir, & Gebre-Amanuel, 
2016, p.70).  Low utilization is inefficient and increases 
production cost per unit.   
SC1.6.3. Technology 
In recent years, some improvements have been 
made to logistics in Ethiopia with the introduction of 
technology platforms under the Pharmaceutical Supply 
Agency (ITA, 2020a).  Vitas supports logistics 
management, warehouse management, and inventory 
control to improve purchasing decisions (ITA, 2020a).  
Dagu is similar and supports logistics management and 
inventory control at 700 service delivery points (ITA, 
2020a).  Generally speaking, however, the availability of 
reliable data on both supply chains and customer 
preferences in sub-Saharan Africa is lacking (Lartey et 
al., 2018, p.5; Kaufman et al., 2021; Khanna, Palepu, & 
Sinha, 2005, p.1; Kaine & Nwokike, 2020). 
SC1.7. Ethiopian-Indian relations 
Ethiopian-India relations have enjoyed roughly 
2000 years of trade partnership (“India-Ethiopia 
relations,” 2017, p.1).  Cooperation on political, 
economic, and developmental projects generates 
benefits for both parties. 
Diplomatic relations were formally established 
between the modern countries in 1950 (Purushothaman, 
2018).  Although dealings have traditionally been 
friendly, regime changes in Ethiopia have caused some 
interruptions in cooperation (“India-Ethiopia relations,” 
2017, p.1). Under the communist Derg regime, for 
example, many Indian businessmen and teachers left 
Ethiopia (“India-Ethiopia relations,” 2017, p.1).  
Following the democratic and liberalizing reform of the 
early 1990s, Indian investment in Ethiopia rose 
significantly, especially in infrastructure (“India-
Ethiopia relations,” 2017, p.1, 3). 
Ethiopia became largest recipient of India’s Lines of 
Credit (LOCs) in Africa with a 2015 commitment of $1 
billion by New Delhi (Purushothaman, 2018).  
According to the Indian Ministry of External Affairs, as 
of 2016, bilateral trade was valued at “$1.37 billion, of 
which India’s exports to Ethiopia were $1.3 billion” 
(2017, p.4).  Of this, 13% was attributed to drugs and 
pharmaceuticals (“India-Ethiopia relations,” 2017, p.4).  
India is the country’s third largest importer behind China 
and the United States, contributing 7.7% of all Ethiopian 
imports (“India-Ethiopia relations,” 2017, p.4).  
India is a leading investor with over “540 Indian 
companies in Ethiopia with licensed investment of over 
US $4 billion of which about US $2 billion is estimated 
to be on the ground” (“India-Ethiopia relation,” 2017, 
p.4).  Primary investment sectors include 
pharmaceuticals, manufacturing, and healthcare (“India-
Ethiopia relations,” 2017, p.4).  Joint venture Cadila 
Pharmaceuticals PLC is one such investment example 
(see: Case Study B3) (“India-Ethiopia commercial,” n.d.; 
EFDRE, 2015, p.2).   
The Indian Technical and Economic Cooperation 
(ITEC) program supports education and capacity 
building in Ethiopia by providing training for Ethiopian 
students at Indian universities (Purushothaman, 2018).  
Between 2007/2008 and 2016/2017, the number of ITEC 
slots for Ethiopian students has been expanded tenfold 
(Purushothaman, 2018).  Other programs, including 
scholarships from the Indian Council of Cultural 
Relations, agreements on Cooperation in Science and 
Technology, and investment in agricultural, textile, and 
energy projects have “helped India build immense 
goodwill among both the civilians and the defense 
personnel” of Ethiopia (“India-Ethiopia relations,” 2017, 
p.8-9; ITA, 2020a; Purushothaman, 2018).  Diplomatic 
relations are currently close, as Ethiopia Airlines 
currently offers daily flights to Mumbai and New Delhi 
and Indian presence is particularly pronounced among 
Ethiopian higher education institutions (“India-Ethiopia 
relations,” 2017, p.10). 
Figure C2 
Map of Ethiopia 
 









Standard World Map 
 
Source: Mohamed, 2018, p.27 
Figure C4 
World Map Adjusted for Pharmacists Working 
 
Source: Mohamed, 2018, p.31 
Supplement C2: Rwanda Additional Information 
SC2.1. Historical background 
Rwanda is located in Central East Africa and 
borders Uganda, Tanzania, Burundi, and the Democratic 
Republic of the Congo (DRC).  With a geographic area 
smaller than that of Maryland with over 12 million 
citizens, Rwanda is one of the most densely populated 
countries in Africa (CIA, 2021d).  Figure C5 provides a 
map. 
Rwanda’s colonial and post-colonial history is 
rather tumultuous, having been conquered by the 
Germans in 1898 and then captured in 1916 by Belgium 
(CIA, 2021d).  Under both colonial regimes, the Tutsi 
ethnic group was favored (CIA, 2021d).  Ethnic tensions 
came to a head in 1959, three years before independence 
from Belgium, when the majority ethnic group, the 
Hutus, organized a coup against the Tutsi king.  (CIA, 
2021d).  Over the next several years, thousands of Tutsis 
were killed or exiled, the children of the latter group 
ultimately forming the Rwandan Patriotic Front (RPF), a 
rebel group that would start a civil war in 1990 (CIA, 
2021d).  The civil war culminated in a 1994 state-
orchestrated genocide (CIA, 2021d). 
Rwanda is now a presidential republic divided into 
four provinces and one city (CIA, 2021d).  It’s first post-
genocide presidential and legislative elections were held 
in 2003, the same year as the signing of its new 
constitution (CIA, 2021d).  Rwanda uses a mixed legal 
system of German- and Belgian-inspired civil law and 
customary law (CIA, 2021d).  Its current heads of state 
are President Paul Kagame and Prime Minister Edouard 
Ngirente (CIA, 2021d). 
SC2.2. Pharmaceutical industry structure 
The Rwandan pharmaceutical market can be 
subdivided as follows: (a) government-operated 
manufacturers and (b) private importers (USAID, 2016, 
p.1).  As of 2018, there was no local production by 
MNCs (US Department of Commerce [USDOC], 2018).  
According to a 2018 audit, the Pharmaceutical 
Laboratory of Rwanda’s (LABOPHAR) production 
stopped in 2013 (Hakizimana, 2021).  Indian 
pharmaceuticals dominate the market through imports, 
reaching Rwandan consumers through wholesalers who 
jack up prices and increase uncertainty (Uwizeyimana et 
al., 2021, p.3). 
The Medical Procurement and Production Division 
(MPPD) of the Rwanda Biomedical Center (RBC) 
currently “performs the procurement, storage, and 
distribution of health commodities to public health 
institutions” and is considered to be the central medical 
store (Uwizeyimana et al., 2021, p.3).    However, 
existing regulations prevent MPPD from “importing 
pharmaceuticals directly from international 
manufacturers” (Uwizeyimana et al., 2021, p.3).    
Consequently, MPPD use intermediate suppliers who 
import the drugs themselves, adding an additional link in 
the supply chain and increasing prices (Uwizeyimana et  
In the private sector, wholesale pharmaceutical 
companies import directly from international 
manufacturers and sell to community pharmacies, 
private health clinics, and hospitals (Uwizeyimana et al., 
2021, p.2).    In both cases, India is the major supplier 
(USDOC, 2018). 
SC2.3. Local production capacity 
Like Ethiopia, Rwanda’s business environment 
offers a mixed bag for potential investors.  In both 
countries, if one acknowledges the structural cost 
barriers, the key to pharmaceutical manufacturing 
feasibility is volume.  Market access must be secured by 
government intervention, at least in beginning stages of 
industry development. 
The Rwandan government, much like Ethiopia, has 
M. Bradley University of South Carolina Honors College (2021) 
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implemented some measures to this effect.  Rwanda’s 
growing middle class is a selling-point for potential 
investors.  Even more significant is the country’s 
membership in the East African Community (EAC), a 
customs union of over 177 million potential customers 
(ITA, 2020b).  Recognizing this appeal, since the 1990s, 
Rwanda has streamlined business registration to now 
take just one day (USDOC, 2018). 
However, instead of acting as the starting point for 
investment, Rwanda has used the EAC as a constraint.  
By favoring the Community in import duties, hiring, and 
visa registration, Rwanda disadvantages European, 
Indian, and Chinese investment (ITA, 2020b).  Other 
limitations include “delays in government payments for 
services or goods delivered, changes in MOU conditions 
during contract negotiations, and/or additional tax 
assessments” as well as “inconsistent application of tax 
incentives and import duties” (ITA, 2020b).  Like 
Ethiopia, despite efforts to improve local production, 
regulation remains complex and inadequate (USAID, 
2016, p.1). 
In terms of input materials, Rwanda is much like 
Ethiopia in that it is fully reliant on imports of raw 
pharmaceutical materials like APIs, excipients, and even 
machinery spare parts (USAID, 2016, p.3).  For both 
countries, India is among the main import sources 
(“India-Rwanda relations,” 2013, p.4).  The two 
countries also share high electricity costs, though 
Rwanda’s rates exceed those of “other East African 
countries and rank in the top ten most expensive tariffs 
in sub-Saharan Africa” (ITA, 2020b; USAID, 2016, p.1).  
Both countries being landlocked, all trade must be 
conducted by road or air despite relatively limited 
infrastructure, which increases lead times and 
transportation costs (ITA 2020b, CIA, 2021d).  These 
expenses increase the total cost of production (USAID, 
2016, p.1). 
As in Ethiopia, access to financing in Rwanda is 
challenging, with “high interest rates and limited local 
capital markets” (ITA, 2020b).  Rwanda also shares 
Ethiopia’s lack of skilled labor (ITA, 2020b). 
expected to improve generation capacity by nearly 50% 
(“India-Rwanda relations,” 2013, p.3).  Also like 
Ethiopia, Rwanda enjoys Indian support of education 
with ITEC slots and Indian professors at Rwandan 
universities (“India-Rwanda relations,” 2013, p.3-4).  
Though Rwanda does not currently have a DTAA with 
India, diplomatic and trading relations remain close. 
Figure C5 
Map of Rwanda 
 
















SC2.4. Rwandan-Indian relations 
Indian-Rwandan relations are positive and have 
improved since their official recognition in 1999 (“India-
Rwanda relations,” 2013, p.1).  India’s interest in 
Rwanda increased dramatically following the latter’s 
membership in regional economic communities such as 
the EAC (“India-Rwanda relations,” 2013, p.1).  Like 
Ethiopia, Rwanda is the recipient of an $80 billion EXIM 
Bank Line of Credit for a hydroelectric power project 
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